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PREFACE 
May the fundamental goal of this project be achieved, for women at-risk for hereditary breast 
cancer to justly and promptly gain this knowledge, in order to guide preventive health care 
actions that promote optimal quality and quantity of life. 
 
“Health, the greatest of all we count as blessings.”  – Ariphron  
 
“Think left and think right and think low and think high.  Oh, the thinks you can think up if only    
you try!”                      – Dr. Seuss 
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ABSTRACT 
Breast cancer is the foremost new cancer diagnosis and the second highest cause of cancer 
death in American women (American Cancer Society, 2019).  Hereditary breast cancer is most 
commonly caused by a mutation within the breast cancer susceptibility genes, BRCA 1 or 2, 
which increases women’s risk for breast cancer by five to ten-fold the average population (Mayo 
Clinic, 2019).  The U.S. Preventive Services Task Force has assigned a Grade B 
recommendation advising health care providers to use a risk assessment tool, such as the 
Breast Cancer Genetics Referral Screening Tool (B-RST™), to recognize and provide medical 
management recommendations for high-risk women (Nelson, Pappas, Cantor, Haney, & 
Holmes, 2019).  Offering medical management options to this at-risk group can promote breast 
cancer prevention or early detection to positively affect health outcomes (ACOG, 2019; Kiely & 
Schwartz, 2014).  The purpose of this evidence based practice (EBP) project was to determine 
if using the B-RST™ would aid in identifying women who are candidates for cancer genetic 
and/or High Risk Breast Clinic (HRBC) counseling, in comparison to the approach of reviewing 
cancer family history in the electronic medical record (EMR).  The seven steps of the Iowa 
Model (Iowa Model Collaborative, 2017) guided this EBP protocol implementation.  During a 12-
week time period 994 women seen at a nine provider obstetrical and gynecological practice in a 
Midwestern state had a B-RST™ assessment performed during routine gynecological and new 
patient appointments.  Data were collected by completing and recording the B-RST™ results in 
the EMR, reviewing populated reports, and performing chart audits.  Additionally, chart audits 
established participation in scheduling and attending referral consultation appointments.  
Demographic information was obtained for the pre-protocol patient group (N = 880) along with 
genetics (N = 8) and HRBC (N = 6) referrals for the same 12-week time period one year prior.  
During this EBP project, a total of 994 participants had the B-RST™ assessment performed.  
Genetics referrals were provided to 32 (18.4%) of the 174 participants who qualified, with six 
(21.9%) of the appointments completed.  From the 249 participants eligible for a HRBC 
xi 
 
consultation, 57 (22.9%) received referrals and eight (14.0%) participants had this performed.  A 
Chi-square test for independence resulted in p values > .05 for the variables of age, 
appointment type, insurance, race, and religion; thus determining the sampling was 
representative of the office population.  Factorial ANOVA analyses were statistically significant 
for the effects of the health care providers using the B-RST™ to guide both HRBC (F(6, 1860), 
= 9.23, p <.001) and genetics (F(6, 1860) = 6.46, p < .001) referrals.  It was determined that use 
of the B-RST™ was an effective method for identifying, and subsequently providing appropriate 
referrals, to women who are at-risk for hereditary breast cancer at an Ob/Gyn office setting.  
Future EBP projects and research should focus on methods to: (a) educate health care 
providers about hereditary breast cancer, its associated risks, and B-RST™ use to promote risk 
assessment utilization, (b) increase health care provider HRBC and genetics referral rates to 
provide identification and medical management for those at-risk, and (c) recognize and address 
patient-reported barriers to improve referral acceptance and participation rates.   
 Keywords: BRCA 1 or 2, breast cancer, Breast Cancer Genetics Referral Screening 
Tool, B-RST™, genetics referral, hereditary breast cancer, High Risk Breast Clinic, protocol, 
referral 
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CHAPTER 1 
INTRODUCTION 
Background 
 Being diagnosed with cancer is a formidable reality that many individuals face.  In the 
United States (U.S.), cancer is second only to cardiovascular disease for leading causes of 
death (Centers for Disease Control and Prevention, 2018).  In American women, breast cancer 
is currently the foremost new cancer diagnosis and the second highest cause of cancer death.  
In 2019, it is estimated there will be 268,600 new breast cancer cases in women in the U.S. and 
that 41,760 will die from this cancer (American Cancer Society [ACS], 2019).  Many factors 
influence women’s risk of acquiring breast cancer.  An important role of a health care provider is 
assessing and identifying women who have an elevated predisposition for breast cancer, in 
order to offer additional medical management options which promote breast cancer prevention 
or early detection (Cusack Jr & Hughes, 2012; Kiely & Schwartz, 2014).  
 Risk factors for breast cancer are categorized as non-modifiable and modifiable.  
Female gender and advancing age, predominantly beyond 50 years old, are two primary non-
modifiable risks (ACS, 2017a; Kiely & Schwartz, 2014; Smith, Mester, & Eng, 2014).  According 
to the ACS (2017a), additional non-modifiable risk factors include: (a) ethnicity; (b) race; (c) 
family history of breast cancer; (d) hereditary breast cancer gene mutations; (e) fetal exposure 
to diethylstilbestrol; (f) early menarche; (g) late menopause; (h) dense breast tissue; (i) specific 
benign breast conditions; and (j) prior chest radiation before 40 years old.  Modifiable risk 
factors for the development of breast cancer include: (a) lack of physical activity; (b) being 
overweight or obese; (c) consuming more than two or three units of alcohol daily; (d) being 
nulliparous; (e) not breastfeeding; (f) using certain forms of contraception; (g) taking combined 
hormone replacement therapy after menopause (ACS, 2017b).  For the purpose of this 
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evidence-based practice (EBP) practice project, the primary emphasis is the non-modifiable risk 
factor of the hereditary breast cancer gene mutations BRCA1 and 2. 
 Thoroughly reviewing an individual’s personal and family cancer histories assists in 
differentiating between hereditary, familial, and sporadic breast cancers.  It is estimated that 5-
10% of breast cancers are hereditary, 15-20% are familial, and the remainder are considered 
sporadic (Meaney-Delman & Belcross, 2013).  Hereditary breast cancer “red flag” 
characteristics include any of the following personal and family histories: (a) breast cancer prior 
to 50 years old, (b) breast and/or ovarian cancer in multiple family members in many 
generations, (c) bilateral breast occurrence and/or multiple metastases spread from the same 
primary site, (d) incidence of less prevalent cancers (e.g., fallopian tube, ovarian, peritoneal, 
male breast), (e) one or more diagnosed gene mutations, and (f) certain populations (e.g., 
Ashkenazi Jewish) (Meaney-Delman & Bellcross, 2013).  Familial breast cancers typically occur 
after the age of 50 years old, are in several family members without a pattern, tend to be 
unilateral, and are noted to have an association between genetics and one’s environment 
(Meaney-Delman & Bellcross, 2013; Smith et al., 2014).  In contrast, the majority of breast 
cancer occurrence is considered sporadic with onset after 60 years old, occurs unilaterally, is 
unassociated with familial rates of breast or other related cancers, and is often associated with 
environmental and modifiable risk factors (Meaney-Delman & Bellcross, 2013).     
 In 2003, one of the most significant advancements in medicine occurred when 
sequencing of the human genome was completed (National Institutes of Health [NIH], 2017).  
Since then, much has been learned about the genome, or entire collection of genes, comprising 
the human body (NIH, 2017).  Inherited changes within a gene, classified as a mutation or a 
pathogenic variant, can increase an individual’s predisposition for cancer development 
depending on the specific gene and location of the modification (Buys et al., 2017; NIH, 2017).  
Inheriting a gene mutation from one or both parents increases the likelihood of cancer 
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occurrence and accounts for up to 10% of breast cancer diagnoses (ACS, 2017a; Senter & 
Hatfield, 2016). 
 The most common cause of hereditary breast cancer evolves from germline mutations of 
breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2); 
hereafter collectively referred to as breast cancer gene (BRCA), unless noted otherwise 
(Bayraktar & Arun, 2017; Smith et al., 2014).  All individuals have these two genes, which 
ordinarily serve the purpose of generating proteins that inhibit tumor production (NIH, 2018).  In 
an individual with a BRCA mutation, cancer cells are allowed to proliferate when damaged DNA 
is not corrected properly (NIH, 2018).  An estimated 1/300 to 1/500 individuals have a BRCA 
gene mutation (Nelson, Pappas, Cantor, Haney, & Holmes, 2019).  Women of Ashkenazi 
Jewish descent have an even higher predisposition of 1/40 of inheriting this gene mutation 
(McReynolds, 2017).  Whereas the average American woman has an estimated 12% lifetime 
risk of breast cancer, women with a BRCA mutation confront a significantly increased lifetime 
risk of up to 72% (McReynolds, 2017).   
 BRCA-related cancers characteristically affect individuals at younger ages with 
increased susceptibility to additional cancer diagnoses during their lifetime (McReynolds, 2017).  
Besides breast cancer, BRCA mutations are also associated with elevated risks for the following 
malignancies: (a) fallopian tube; (b) ovarian; (c) pancreatic; (d) peritoneal; and (e) prostate 
(Bayraktar & Arun, 2017; NIH, 2018).  Melanoma is another malignancy associated specifically 
with BRCA2 (Bayraktar & Arun, 2017; Hampel, Bennett, Buchanan, Pearlman, & Wiesner, 2015; 
Smith et al., 2014).   
 Although there are additional hereditary gene mutations known to elevate breast cancer 
susceptibility, the most prevalent encompass the BRCA1 and BRCA2 mutations (Couch et al., 
2017).  These two mutations are associated with a five to ten-fold increase in lifetime risk for 
breast cancer and represent five to ten percent of breast cancer diagnoses annually (Meaney-
Delman & Bellcross, 2013; Mayo Clinic, 2019; Nair et al., 2015).  Since breast cancer is the 
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predominant BRCA-related malignancy risk, with medical management options available to 
potentially decrease or prevent disease occurrence, the focus of this EBP project is on 
appropriate and timely identification and referral of woman at risk for having this gene mutation.   
Data from the Literature Supporting Need for the Project 
 A widespread consensus exists amidst many professional medical organizations and 
societies emphasizing the importance of obtaining and assessing an individual’s personal and 
family medical histories for inherited hereditary breast cancer risk in order to provide additional 
medical management options.  In August 2019, the U. S. Preventive Services Task Force 
(USPSTF) updated their 2005 recommendation statement for BRCA-related cancer risk 
assessment with an initial online publication.  These guidelines inform the care for the 
population of women who may be at risk of having a BRCA mutation (Nelson et al., 2019).  
According to the USPSTF guidelines, further evaluation and management is suggested when 
any of the following are noted in a family’s cancer history: (a) BRCA-related cancers; (b) breast 
cancer prior to the age of 50; (c) numerous members with breast cancer; (d) cancer affecting 
both breasts; (e) presence of both breast and ovarian cancer; (f) male breast cancer; and (g) 
Ashkenazi Jewish ethnic background (Moyer, 2014).  
 The 2019 USPSTF update again provided a grade B recommendation for risk 
assessment and encouraged use of a screening risk assessment tool for BRCA gene mutations 
in women with a family history of breast and/or ovarian cancer to determine appropriate 
candidates for genetic counseling referrals (Nelson et al., 2019).  A grade B recommendation 
indicates that health care providers should perform this service as it is determined to provide at 
least a moderate benefit to an individual (USPSTF, 2017).  In agreement with the prior update in 
2013, this recommendation continues to support the need to “Screen women whose family 
history may be associated with an increased risk for potentially harmful BRCA mutations.  
Women with positive screening results should receive genetic counseling and, if indicated after 
counseling, BRCA testing” (Moyer, 2014, p. 272).  Although a particular risk stratification tool 
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wasn’t suggested for this screening assessment, of the eight tools evaluated by the USPSTF, 
the Referral Screening Tool (now called B-RST™) and the Seven-question Family History 
Screening are the two that received the highest quality rating of good; the ratings are 
categorized as fair, fair to good, and good (Nelson et al., 2019).   
 The National Comprehensive Cancer Network (NCCN) updates clinical practice 
guidelines at least annually for a multitude of cancers.  Version 3.2019 of Genetic/Familial High 
Risk Assessment: Breast and Ovarian, contains genetic breast cancer assessment criteria that 
are more specific than those delineated by the USPSTF (NCCN, 2019b).  These criteria are 
provided to assist with determining appropriate candidates for hereditary cancer genetic 
services and are differentiated between individuals with and without a history of BRCA-related 
cancers.  According to the NCCN (2019b), an accurate family history assessment incorporates 
all biological female and male family members, which then supports separate evaluation of 
maternal and paternal lineage.  NCCN guidelines are based on EBP, are frequently referenced 
by professional organizations and societies, and guide medical management of individuals at 
increased risk or already affected by cancer (NCCN, 2019b).     
 In a Committee Opinion focusing on family history originally published in 2011 and 
reaffirmed in 2018, The American College of Obstetricians and Gynecologists (ACOG) asserted, 
“Family history information should be reviewed and updated regularly, especially when there are 
significant changes to family history.  Where appropriate, further evaluation should be 
considered for positive responses, with referral to genetic testing and counseling as needed” 
(2018, p.1). Those considered to be at elevated susceptibility should subsequently be referred 
for genetic counseling with testing if determined necessary.  Utilization of a family history 
assessment tool or performance of a minimum of a three-generation pedigree is proposed.  If 
use of a screening tool is preferred, care should be taken to ensure that it is applicable to the 
population of patients within the community where the practice is located (ACOG, 2018).   
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 The Nurse Practitioners in Women’s Health (NPWH) emphasized that hereditary breast 
cancer risk assessment needs to be part of routine care (NPWH, 2017).  This risk evaluation 
ideally incorporates (a) the cancer history of the individual and her first-, second-, and third-
degree maternal and paternal relatives, (b) detailing the age at diagnosis, and (c) location of the 
primary cancer.  In addition, it is important to determine if there is Ashkenazi Jewish heritage 
and genetic test results available for any relatives (NPWH, 2017).  This organization 
recommended the use of screening tools to determine appropriate candidates for genetic 
counseling with possible testing.  In congruence with USPSTF and ACOG guidelines, specific 
screening tools weren’t recommended, but having a strategy for approaching a hereditary 
breast cancer risk assessment is necessary.  “A system should be established within WHNPs’ 
[Women’s Health Nurse Practitioners’] practice settings for referral, consultation, and/or 
collaboration to ensure that women have timely access to genetic counseling services and 
subspecialty follow-up” (NPWH, 2017, para. 4). 
 The American College of Medical Genetics and Genomics and the National Society of 
Genetic Counselors collaborated and released clinical guidelines for cancer assessment 
referrals (Hampel et al., 2015).  These organizations recognized the challenging barriers health 
care providers confront with timely identification and management of individuals at elevated 
propensity for developing cancer.  Similar to the NCCN guidelines, criteria for genetic referrals 
are based on specific risk factors that encompass personal and family history attributes (Hampel 
et al., 2015). 
 According to Cotton and Kirkpatrick (2017), merely one of the fourteen million women in 
the U.S. who qualify for BRCA testing have actually performed genetic testing.  It is estimated 
that amongst individuals who have a BRCA gene mutation, only 30% of breast cancer survivors 
and 10% without a history of BRCA-related cancer have been identified through genetic testing 
(Drohan, Roche, Cusack, and Hughes, 2012).  Besides the potential health consequences, not 
assessing risk factors and offering genetic services can result in medical malpractice lawsuits.  
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For breast cancer lawsuits, the highest in frequency and payouts occur with women who are 
younger than 50 years old, often related to an increase in cancer aggression and fatality rates 
(Cotton & Kirkpatrick, 2017).  To apply an understanding of potential hereditary cancer risks to 
all aspects of a woman’s health care, Snow (2014) strongly encourages hereditary cancer risk 
assessment performance at each office visit.  Furthermore this physician asserts, “preventing 
life-threatening illness, such as hereditary cancer, is the most important part of our job” (Snow, 
2014, p. S4).     
Data from the Clinical Agency Supporting Need for the Project 
 Between the years of 2011 and 2015, Lake and Porter counties in Northwest Indiana 
had an average of 395 and 127 annual cases of breast cancer respectively, making them the 
2nd and 7th leading counties of breast cancer prevalence in this state (State Cancer Profiles, 
2015).  In the state of Indiana, approximately 5,820 new cases of breast cancer in women are 
predicted to occur and nearly 870 will succumb to this condition in the year 2019 alone (ACS, 
2019).  From June 1, 2018 to June 1, 2019, over 21,500 patient appointments occurred at an 
obstetrical and gynecological (Ob/Gyn) practice with five offices locations at that time in 
Northwest Indiana (H. Hendricks, personal communication, June 3, 2019).  Amongst these 
appointments, 3,415 were for routine gynecological examinations and 1,746 were new patients 
establishing care.  This practice currently employs three physicians, three nurse practitioners 
(NPs), and three certified nurse midwives (CNMs).  Within this practice group, collaborative 
agreements exist between the advanced practice registered nurses (APRNs) and the 
physicians, but each practitioner provides patient care with a relatively independent approach 
(L. Williams, personal communication, June 11, 2019).  This Ob/Gyn practice does not have a 
protocol for the method in which patients are screened and offered referrals for genetic 
counseling and testing (L. Williams, personal communication, June 11, 2019).  Currently, there 
is a lack of consistency for assessing, and/or documenting assessing, women’s personal and 
family medical histories for hereditary breast cancer risk.  Therefore, depending upon the 
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provider a patient is scheduled to see in this practice group, only a portion of women who are 
appropriate candidates for hereditary breast cancer risk assessment may be evaluated and 
offered a referral for genetic screening services and subsequent follow-up.  Development and 
utilization of an EBP protocol will promote more consistent and thorough care of this at-risk 
population of women. 
Purpose of the Evidence-Based Practice Project 
 The purpose of this EBP project is to answer the following compelling clinical question: 
In an obstetrical and gynecological practice, what is the best clinical practice for implementing a 
protocol for identifying women at increased risk for hereditary breast cancer, in order to refer 
appropriate candidates for genetic services?  Additional queries consider whether the health 
care providers and support staff will consistently utilize the protocol; and, in order to determine 
strategies to improve protocol adherence, what are identified barriers and benefits to its use? 
PICOT Question 
 Clinical inquiry promotes the continuous advancement of EBP.  The PICOT format is 
commonly utilized to guide the process of formulating the EBP question (Adams, 2015; Fineout-
Overholt & Stillwell, 2019).  The “P” represents the specific population or problem of concern.  
“I” stands for the intervention or issue that is of importance.  The “C” delineates the comparison, 
such as when an intervention is contrasted to a specific standard of care.  “O” is for the 
identified and measured outcome(s).  If applicable to the topic, the “T” designates a reference of 
time.      
 The PICOT question for this EBP project is:  In women cared for in an obstetrical and 
gynecological practice (P) how does utilization of a breast cancer genetics referral screening 
tool (I) as compared to the current standard of care of collecting and reviewing family history in 
patients’ electronic medical record (C) allow women at increased risk for hereditary breast 
cancer to be appropriately identified and referred for genetic counseling (O) within a twelve-
week time frame (T)? 
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Significance of the EBP Project 
 Protocols provide structure and consistency amongst health care providers in a group 
practice.  ACOG promotes protocol development and utilization to facilitate complying with 
standards while providing continuity of care, which has demonstrated improved patient safety 
(2019).  To promote successful utilization, ACOG (2019) suggests health care providers should 
be “. . .engaged in the process of developing guidelines and presenting data to help foster 
stakeholder buy-in and create consensus, thus improving adherence to guidelines and 
protocols” (p. 1).  The NPWH (2017) agree that, “An evidence-based protocol established 
according to guidelines provided by nationally recognized organizations such as NCCN must be 
followed to ensure that all recommended components of assessment, counseling, informed 
consent, appropriate testing, and follow-up are followed” (para. 3).   
 With the ultimate goal of decreasing hereditary breast cancer incidence, timeliness of 
BRCA gene mutation identification can provide additional opportunity for utilization of preventive 
medical management options for cancer risk modification (Drohan et al., 2012; Guo et al., 2017; 
Profato & Arun, 2015; Randall & Pothuri, 2016; Snow, 2014).  Nair et al. (2015) reports, “The 
identification of BRCA mutation carriers, coupled with risk reduction strategies, has been shown 
to lower the incidence of both breast and ovarian cancer, as well as cancer specific and all-
cause mortality” (p. 119).  Meaney-Delman and Bellcross (2013) specify that guidelines from the 
NCCN comprise the most comprehensive, current, and widely utilized cancer risk reduction 
recommendations.  Strategies for breast cancer risk reduction include the following: (a) breast 
self-awareness; (b) lifestyle factor modification (e.g., alcohol consumption, breastfeeding, 
exercise, combination hormone replacement therapy use); (c) once to twice yearly clinical 
breast examination; (d) once yearly mammography and breast magnetic resonance imaging 
(MRI); (e) use of a risk-reducing medication from the aromatase-inhibitor or selective estrogen-
receptor modulator categories; (f) bilateral mastectomy; (g) bilateral salpingo-oophorectomy; 
and (h) clinical trial participation (NCCN, 2019a).   
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 Particularly in women at-risk for hereditary breast cancer, the use of specific medical 
management options can lead to breast cancer reduction and improved survival rates (Meaney-
Delman & Bellcross, 2013).  Multiple studies have demonstrated that bilateral prophylactic 
mastectomy provides a 90% breast cancer risk reduction (Johns, Agarwal, Anderson, Ying, & 
Kohlmann, 2017).  Further studies indicated a reduction of ovarian cancer by 86% when a risk-
reducing bilateral salpingo-oophorectomy was performed, with an additional decrease in breast 
cancer risk when this surgical procedure was performed prior to menopause (Johns et al., 2017; 
Randall & Pothuri, 2016).  Although women may initially be counseled by a geneticist, surgeon, 
or oncologist regarding risk-reducing recommendations, it is important that health care providers 
are familiar with guidelines and subsequent revisions for breast surveillance, medication, and 
surgical opportunities in this at-risk group.  
 A primary objective for this EBP project coincides with that of ACOG, “With increased 
awareness of the importance of family history as a screening tool and of the values of 
preventive measures and increased surveillance, there is hope for improved outcomes” (ACOG, 
2018, p. 1).  It is suggested that following the proposed EBP protocol, including the use of a 
breast cancer genetics referral screening tool, will provide women who are cared for at this 
Ob/Gyn practice with more consistent and thorough assessment of their individual risk of 
hereditary breast cancer regardless of the provider they are seeing.  Women who are then 
determined to be at high risk for hereditary breast cancer can be offered further management 
options, to include genetic counseling with possible testing, allowing for a high level of care 
consistent with current organization and society guidelines.   
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CHAPTER 2 
EBP MODEL AND REVIEW OF LITERATURE 
Evidence-based Practice Model 
Overview of EBP Model 
 Evidence-based practice encompasses the pursuit to provide the greatest quality of 
health care based on the highest level of knowledge available (Doody & Doody, 2011).  
Professional expertise and patient predilection are additional components of EBP (Schmidt & 
Brown, 2015).  EBP models facilitate the integration of this evidence into clinical practice with 
the objectives of optimal or improved patient outcomes (Doody & Doody, 2011).  The Iowa 
Model of Evidence-Based Practice to Promote Quality Care, hereafter referred to as the Iowa 
Model, was utilized for structuring this EBP project.  Founded upon Martha Roger’s Diffusion of 
Innovations theory, the Iowa Model was originally created in 1994 by Marita G. Titler and fellow 
nurses at the University of Iowa Hospitals and Clinics (Iowa Model Collaborative et al., 2017).  
The Iowa Model has been revised several times, with the most recent update occurring in 2015 
(Iowa Model Collaborative et al., 2017).  This model is often the foundation for implementing 
new guidelines into an organization to enhance the quality of care and therefore was 
determined to be ideal for providing direction for this EBP project of a protocol implementation at 
an Ob/Gyn practice (Iowa Model Collaborative et al., 2017; Schaffer, Sandau, & Diedrick, 2013). 
 With the most current revision, the Iowa Model Collaborative et al. (2017) delineates the 
model’s seven steps, in addition to three opportunities to determine if the process can occur 
based on necessary relevance and evidence to pursue the change.  The first step is to choose 
the topic, which is often generated by an update in knowledge or a current obstacle in ideal 
patient care provision.  The focus or problem is identified during the second step.  The PICOT 
format is often used to provide further clarity during this task.  After completion of these initial 
two steps, one must pause and determine if the focus or problem is a sufficient enough of a 
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concern to pursue.  If it is determined to be adequate at this initial checkpoint, the process 
continues; if it isn’t, another topic should be considered.  
 Choosing team members is the third step.  Team members will collaborate with creating 
and integrating the EBP change and should include key stakeholders (Doody & Doody, 2011; 
Iowa Model Collaborative et al., 2017).  The team will then initiate the fourth step, which is 
obtaining and evaluating the evidence.  An appraisal tool is chosen to classify the quality of the 
information collected.  Upon reviewing the appraised evidence, the second occasion and 
checkpoint arises to consider if the evidence supports the change.  If it does reinforce EBP, 
continuation to the following step can occur; if it doesn’t, further research efforts are necessary.      
 The fifth step is the generation and trial performance of the EBP change (Iowa Model 
Collaborative et al., 2017).  This pilot process is unique amongst the EBP models and includes 
evaluating data and reporting the change’s effectiveness.  The third opportunity occurs to 
decide if this change should be approved for continued use.  If it is supported, the final 
checkpoint completion permits the last two steps to be initiated; if it isn’t, it is necessary to 
consider different procedures in which to implement the change. 
     During the sixth step in the Iowa Model, the EBP change is permanently established 
(Iowa Model Collaborative et al., 2017).  This step requires strategies to manage and reinforce 
these changes.  Concluding with the seventh step is providing communication about the change 
outcome.  This can range from providing education and updates at a staff meeting, to more 
widespread endeavors, such as a conference presentation or a journal publication (Iowa Model 
Collaborative et al., 2017).  This final process of the Iowa Model promotes further advancement 
of EBP. 
Application of EBP Model to DNP Project 
 Using the Iowa Model to guide this EBP project (see Appendix A), the first step of topic 
identification was initiated when it was observed that women at an Ob/Gyn practice were not 
consistently being assessed for their risk of hereditary breast cancer and then as appropriate, 
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being offered a referral for genetic services.  The topic chosen became hereditary breast cancer 
risk assessment.  For the second step, the PICOT format was applied.  In women cared for in 
an obstetrical and gynecological practice (P) how does utilization of a breast cancer genetics 
referral screening tool (I), as compared to the current practice of collecting and reviewing family 
history in patients’ electronic medical record (C), promote women at increased risk for hereditary 
breast cancer to be identified and referred for genetic counseling (O) within a twelve-week time 
frame (T)?  This topic was then determined at this initial checkpoint to be an appreciable 
concern at this Ob/Gyn practice for this process to proceed. 
 Choosing team members for this EBP change was the third step.  The key stakeholders 
were the health care providers at this practice, consisting of CNMs, NPs, and physicians.  The 
managers, medical assistants (MA), and registration representatives (receptionists) are also 
integral representatives of this team.  Epic is the electronic medical record (EMR) system used 
in this health care practice and an Epic information technologist has been recruited for 
assistance with this EBP project.  A literature search was performed during the fourth step to 
evaluate the current EBP pertaining to this topic.  Multiple databases were employed with a 
variety of systematic reviews and studies obtained and reviewed.  The level and quality of these 
pieces of evidence was established.  The reviewed literature consistently supported the urgency 
of assessing women’s risk for hereditary breast cancer.  Upon identification of women at-risk for 
hereditary breast cancer, genetic counseling promotes early detection of BRCA gene mutations 
along with the ability to review medical management options.  At this checkpoint, the evidence 
reinforced both the focus and the need for this EBP project and supported its continuation. 
 Protocol development was the catalyst for the fifth step.  This was anticipated to be one 
of the most time consuming portions of this process.  The protocol specifically designated the 
process for evaluating women’s risk for hereditary breast cancer and clarified each team 
member’s role in this endeavor.  Team members were educated on their specific responsibilities 
for the protocol utilization through individual and/or group meetings.  Those who are unable to 
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attend the meetings were contacted via email and provided protocol and specific role 
information with request for feedback and questions.  A web-based version of the breast cancer 
genetics referral screening tool (B-RST™) was used to determine if a patient was at-risk for 
hereditary breast cancer.  To allow for both convenience and timeliness, the Epic charting 
system contained a hyperlink within the flowsheet portion of the EMR that went directly to the B-
RST™ website.  Within this fifth step was implementation of the protocol with data collection.  
Prior to protocol implementation, data for the total genetics and High Risk Breast Clinic referrals 
ordered by each of the providers at this Ob/Gyn office was obtained for the 12-week time period 
of September 24, 2018 through December 14, 2018.  To evaluate the pilot portion of this 
change process, this data was compared to the number of genetic and High Risk Breast Clinic 
services referrals provided by each health care provider and in total.  Each week a report was 
run through the EMR in order to evaluate the adherence of the protocol implementation.  Data 
synthesis allowed the opportunity to obtain feedback regarding each health care provider’s use 
of the tool.  In addition, team member evaluation was requested in person and/or by email for 
communication about what was working effectively and/or not as well, in order to enhance 
progression of this change.  Any modifications for improving the efficacy for this protocol and 
augmenting the likelihood for a successful change were then communicated to each team 
member through meetings and/or emails.  During this last checkpoint of the process, data 
analysis coupled with team member feedback aided in deciding if the process for change was 
effective and could continue for the planned twelve weeks. 
 The sixth step incorporated continued use of the protocol with the goal of long-term 
implementation.  Consideration for planning efforts to maintain this change in practice occurred 
simultaneously with periodic monitoring for consistency of tool use dependent upon each team 
member’s role.  As included in the previous step, team member feedback was requested every 
two weeks; this occurred more frequently if protocol compliance was noted to have decreased.  
Team members continued to be updated if any portions of the process were altered. 
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 The seventh and final step was to communicate results of the EBP project to the team 
members.  Once again, this took place at individual or group meetings and/or through emails.  
Additional options for disseminating EBP project results include presenting findings at a local of 
national professional organization’s conference and/or a journal publication.  With the 
conclusion of this step, it will be integral that assessments occur periodically to promote 
sustainability of this change remaining an office-based standard of care. 
Strengths and Limitations of EBP Model for DNP Project 
 Prior to and during its application to this EBP project, it was necessary to consider the 
strengths and limitations of the Iowa Model.  Strengths included that the model was: (a) 
thorough with seven detailed steps; (b) structured, although still allowing the flexibility of an 
individual approach to the process of change; (c) up to date with recent modifications validated 
since 2015; (e) readily available to use with permission; (f) designed with three checkpoints to 
determine if continuation of the change is appropriate to further pursue; and (g) unique with step 
five’s feature of a pilot process, allowing a trial period with evaluation of the results.  Additional 
strengths consisted of the ability of anyone from beginner to expert status to use this model, its 
application to diverse settings, and feedback from more than 600 individuals who had previously 
used this model was provided for the most recent revision (Iowa Model Collaborative et al., 
2017).  Several weaknesses were noted, with one being multiple steps having two to nine tasks 
recommended to accomplish prior to advancing to the next step.  Although a plausible approach 
both ways, steps three (build team) and four (assess evidence) seemed best approached in vice 
versa order, and this was the approach for this EBP project.  Lastly, it would be advantageous 
to have further clarification with specific tips for maintaining a successful change in specific 
health care settings.  Keeping the strengths and weaknesses in consideration, the Iowa Model 
best fit the procedure for this EBP project.       
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Literature Search 
Sources Examined for Relevant Evidence 
 Search engines and key words.  In order to find support for the best practice in 
assessing breast cancer risk, a search of the current literature was conducted using six 
separate databases, including: Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Cochrane Library, Joanna Briggs Institute EBP Database, MEDLINE via EBSCO, 
Nursing & Allied Health Database, and PubMed.  Multiple variations of the search terms were 
attempted, with the following final key search terms used: (1) “breast neoplasms” OR “breast 
cancer;” and (2) “family history” OR genetic OR hereditary OR “high risk” OR inherited OR 
predisposition; and (3) apprais* OR “risk assessment” OR tool*, and (4) refer*.  Related to the 
resource capacity of the Nursing & Allied Health Database, the search terms were limited to: (1) 
“breast neoplasms” OR “breast cancer;” and (2) “family history” OR genetic OR hereditary and 
(3) “risk assessment,” and (4) refer*.  Additional terms not included in the final search were: 
BRCA, consult*, counsel*, evaluat*, familial, gene* refer*, HBOC, model, predict*, and screen*.  
Depending on the database searched, these terms were eliminated based on search results 
either being too extensive or not contributing additional quantity of evidence obtained.   
 Inclusion and exclusion criteria.  Inclusion criteria consisted of: (a) female population, 
(b) published in the English language, (c) published between (January) 2012 through (July) 
2019, (d) scholarly/peer reviewed journals, and (e) academic journals.  Publications were 
excluded for any of the following criteria: (a) the study population was women with a current or 
prior diagnosis of breast cancer, (b) the study focus was on a breast cancer tumor test, gene 
sequencing, or a recurrence score assay, (c) the study population included those with at least 
one family member with a known BRCA gene mutation, (d) the breast cancer risk and/or referral 
tool was used at the time of mammography services only to determine if a woman qualified for a 
breast MRI, (e) the focus was explicitly on care provided by geneticists or other specialists 
providing cancer genetic services, or specific services provided at a High Risk Breast Clinic, (f) 
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the focus was risk for cancers other than breast, (g) the emphasis was on individual breast 
cancer risk perception, or (h) the risk model was used for determining appropriateness of 
chemoprevention. 
 Search results.  Within CINAHL, the search yielded 28 pieces of evidence with 9 
reviewed and 1 accepted without duplicates.  Within the Cochrane Library, 104 were yielded 
within the following categories: 85 Cochrane reviews and 19 Cochrane protocols; 12 were 
reviewed, and 2 were accepted with 1 duplicate.  Within the Joanna Briggs Institute EBP 
Database, 28 were yielded with 5 reviewed and 1 accepted without duplicates.  Within 
MEDLINE via EBSCO, 153 were yielded, with 23 reviewed, with 3 accepted with 2 duplicates.  
Within Nursing & Allied Health Database, 372 were yielded with 31 reviewed and 3 accepted 
without duplicates.  Within PubMed, 144 were yielded with 20 reviewed, with 7 duplicates, and 
without new evidence discovered.  In addition, Google Scholar and Trip Medical Database were 
accessed several times with the inability to limit the final search results to less than 400 
resources.   
 Within these six databases, a total of 829 pieces of evidence were obtained.  With the 
inclusion and exclusion criteria established, 100 abstracts were reviewed, and subsequently 25 
pieces of evidence were then read in their entirety.  Seven duplicates were discovered amongst 
the different databases.  Fifteen pieces of evidence were excluded due to weak support of this 
EBP project, resulting in a total of 10 pieces of evidence for final review.  See Table 2.1 below 
for the results of the literature search.    
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Table 2.1   
Literature Search 
_______________________________________________________________ 
Database  Yielded Duplicates Reviewed Accepted  
_______________________________________________________________ 
 
CINAHL       28        0         9        1 
 
Cochrane   
  Reviews       85        1       12        2 
  Trials        19 
 
JBI        28        0         5        1 
 
MEDLINE     153        2       23        3   
 
Nursing & Allied     372        0       31        3 
Health 
 
PubMed     144        7       20        0 
 
Total      829      10     100      10 
_______________________________________________________________  
Note. CINAHL is the Cumulative Index of Nursing and Allied Health Literature. 
JBI is the Joanna Briggs Institute.     
 
 
Appraisal of Relevant Evidence 
  Appraisal tool utilization.  In order to support changes within health care based on 
EBP, it is essential that current evidence is appraised.  This appraisal consists of ranking the 
level and quality of evidence with evidence hierarchies (Long, 2015).  Higher levels and/or 
qualities of evidence provide a solid foundation for change.  The Johns Hopkins Nursing 
Evidence-Based Practice Model is a model focused on the application of EBP and nursing.  
Multiple tools are available for evidence evaluation along with directing the EBP process (Dang 
& Dearholt, 2017).  Both the level and quality ratings for this EBP evidence appraisal were 
ranked utilizing the 2017 edition of the Evidence Level and Quality Guide from the Johns 
Hopkins Nursing Evidence-Based Practice (see Appendix B).  This tool categorizes five levels of 
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evidence between Level I through Level V with a hierarchy approach and are further described 
as follows (Dang & Dearholt, 2017).  Level I contains the highest level of evidence and is 
comprised of experimental studies, such as a randomized controlled trial (RCT).  Systematic 
reviews of multiple RCTs and explanatory mixed methods using a level I quantitative studies are 
also included in this category.  Level II includes quasi-experimental studies, systematic reviews 
of RCTs and/or quasi-experimental studies, or explanatory mixed methods using a level II 
quantitative study.  Level III consists of non-experimental studies, including systematic reviews 
of multiple study types, exploratory or qualitative studies, and explanatory mixed methods using 
a level III quantitative study.  Level IV encompasses evidence-based guidelines from 
professional medical societies or groups within these organizations, including organization-
specific best-practice recommendations.  Level V incorporates evidence based on background 
and experience and does not include research.  This includes a combination of case reports, 
professional expert opinions, integrative and literature reviews, and programs focusing on 
economics or quality improvement.   
  It is noteworthy that this Evidence Level and Quality Guide tool is more rigorous in 
ranking levels of evidence by differentiating between approaches for studies or evaluation of 
studies, such as explanatory mixed and systematic reviews.  Other appraisal tools group entire 
categories together.  For example, one particular evidence hierarchy organizes and ranks 
systematic reviews and guidelines for EBP at the uppermost level of evidence without 
differentiating between types of studies utilized for each of these (Long, 2015). 
  This appraisal tool also provides guidance for rating the quality of each level of evidence 
with specifications for quantitative and qualitative studies (Dang & Dearholt, 2017).  Evidence 
with higher quality ratings are considered more substantial for use with proposed EBP changes.  
The quality ratings for this tool are as follows: A, high quality; A/B, high/good quality; B, good 
quality; and C, low quality (Dang & Dearholt, 2017).  Each of these rankings has specific 
qualifications depending on which level of evidence is being appraised.  For quantitative studies, 
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high quality evidence incorporates: (a) results that are applicable to similar or other populations 
along with being compatible with other studies and/or current evidence, (b) a study population 
considered to be of adequate measure, (c) sufficient control, and (d) an accurate and detailed 
literature search to support recommendations (Dang & Dearholt, 2017).  Using Dang and 
Dearholt’s (2017) specific terminology, qualitative studies with a high quality or high/good quality 
exhibit the following: (a) transparency, (b) diligence, (c) verification, (d) self-reflection and 
scrutiny, (e) participation-driven inquiry, and (f) insightful interpretation (p. 1).  Table 2.2 below 
summarizes the evidence summary.   
 
 
Table 2.2 
 
Evidence Summary 
____________________________________________________________________________ 
Level  Included Quality                        Design      
____________________________________________________________________________ 
   
   I       2    A (1)  Systematic Review of RCTs (1) 
       B (1)  Randomized Controlled Trial (1) 
 
  II      1    B (1)  Controlled Trial without Randomization (1) 
 
             Pilot Exploratory Study (1) 
                      A (2)  Demonstration Project (1) 
 III      5           A/B (1)  Qualitative Study (1) 
      B (2)  Systematic Review of Combination of Studies (1) 
      Cross-Sectional Study (1) 
       
 IV      2    A (1)  Professional Organization Clinical  
      B (1)  Practice Guideline (1) 
      Evidence Summary (1) 
 
  V      0    
____________________________________________________________________________  
Note. The Evidence Level and Quality Guide from the Johns Hopkins Nursing Evidence-Based 
Practice was used to appraise the evidence. (Dang & Dearholt, 2017) 
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Levels of Evidence 
  Using the Evidence Level and Quality Guide from the Johns Hopkins Nursing Evidence-
Based Practice Model, ten pieces of evidence were appraised encompassing four of the five 
levels of evidence.  Level I evidence included one systematic review of RCTs and one 
randomized controlled trial.  One controlled trial without randomization met the criteria for level 
II.  Level III encompassed the majority of the evidence and consisted of one of each of the 
following: (a) pilot exploratory study, (b) demonstration project, (c) qualitative study, (d) 
systematic review of a combination of studies, and (e) cross-sectional study.  Level IV included 
one evidence summary and one professional organization clinical practice guideline.  There 
were no level V pieces of evidence.  For quality ratings, four pieces of evidence were graded A, 
one was A/B, and five received a B.  See Appendix C for the Evidence Data Table. 
  Level I evidence.  Level I evidence included one systematic review of RCTs and one 
randomized controlled trial.  Hilgart, Coles, and Iredale (2012) performed an updated systematic 
review of RCTs for the Cochrane Database focusing on the impact of breast cancer risk 
evaluation and genetic services.  Studies included women and men across the lifespan who 
were: (a) at-risk for breast cancer related to cancer family history, (b) without a personal history 
of breast cancer, and (c) without a personal known BRCA gene mutation.  Five additional RCTs 
were appraised from the 2007 review to bring the total to eight, with N = 1973.  Outcomes were 
divided into three categories:  (1) Methods for performing risk evaluation; (2) approaches for 
providing genetic health care; and (3) differences between risk evaluation performed by a 
genetic specialist or a non-genetic specialist.  The studies revealed that genetic services 
provided: (a) a decrease in cancer anxiety and enhanced emotional well-being; (b) increased 
personal risk perception accuracy and knowledge concerning breast cancer and genetic 
services, and (c) overall satisfaction with use of genetic services.  The authors concluded that 
hereditary breast cancer risk assessment is an essential process to be performed for 
determining appropriateness of genetic services referrals, with the benefits of genetic services 
HEREDITARY BREAST CANCER PROTOCOL 22 
 
 
considered to outweigh the harms.  Strengths of this systematic review include an extensive 
search strategy, the inclusion and exclusion criteria were precisely presented, high levels of 
evidence were reviewed, the sample size was adequate, and the methods for determining 
biases in the RCTs were thoroughly described and applied.  Weaknesses were the omission of 
summarizing strengths and weaknesses of the studies, potential bias during the literature 
search since terms were not consistent from one database to another, and the inability to 
perform a meta-analysis to determine an effect size due to diversification amongst the RCTs.  
This systematic review was provided a quality rating of A due to the ability to generalize results, 
the large sample size, and conclusions based on EBP.   
The second level I item of evidence was a RCT performed by Kaplan et al. (2014). This 
RCT was comprised of women ages 40 to 74 years old without a previous history of breast 
cancer receiving health care at two U.S. metropolitan primary care medical offices.  The 
population size was sufficient with N = 1235, with the intervention group (n = 580) and control 
group (n = 655) being randomized after baseline phone interviews using statistician-developed 
sequence codes.  The intervention was use of the BreastCARE web-based tool, which stratified 
breast cancer risk by simultaneously using the: (a) Referral Screening Tool, (b) Gail Model, and 
(c) Breast Cancer Surveillance Consortium risk model.  The system for obtaining data was: (1) 
Utilization of the BreastCARE appraisal tool in the intervention group; (2) a one to two week 
post-visit phone survey, and (3) a six month post-visit EMR review.  Outcomes were that use of 
the BreastCARE tool increased: (1) Patient-provider breast cancer risk conversations with OR 
2.07, 95% CI [1.34, 3.20], (2) patient-provider risk reduction conversations with OR 4.78, 95% 
CI, [2.90, 7.89], (3) referrals for genetic services for those at increased risk with OR = 5.32, 95% 
CI, [2.21, 12.8], and (4) EMR charting regarding each of these activities.  Overall, this RCT 
demonstrated that use of a web-based risk evaluation tool enhanced health care provider-
patient discussions about breast cancer risk and medical management options.  Areas of study 
weakness encompassed the potential differences between the two office settings possibly 
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causing a decreased ability to generalize findings; potential biases with individual-reported 
information; and, the need to address health care provider challenges with performing 
hereditary breast cancer risk assessment consistently due to omission of this activity in some of 
the intervention patients.  The sample population was sufficient and data for multiple objectives 
were collected; however, since statistical findings of this RCT did not include information 
regarding instrument reliability and validity and potentially lacking the ability to generalize 
results, it is provided a quality rating of B.     
  Level II evidence.  Level II evidence consisted of a controlled trial without randomization 
performed by Baer et al. (2013).  The study population was new or established female and male 
patients between 18 to 75 years old, without a family history of cancer documented in their 
EMR, presenting for annual examinations within five urban academic primary care medical 
practices.  The sample sizes were adequate with the intervention group consisting of patients 
from three of the practices (n = 996) and the control group from the other two practices (n = 
637).  The study’s purpose was to determine the practicability of implementing the Your Health 
Snapshot web-based hereditary breast and colon cancer risk assessment tool in the primary 
care setting.  The principal outcome was new documentation of cancer family history in the 
EMR within one month of the patient visit.  The secondary outcome was new cancer screening 
test notices initiated within one month of the visit by health care providers for those with an 
increased risk for breast or colon cancer.  Data were obtained from the intervention group 
completing the risk appraisal tool prior to their appointment with review of EMR records one 
month after visits for both groups.  For the first outcome, those in the intervention group had a 
far greater likelihood compared to the control group of having new EMR charting regarding the 
presence of cancer family history (10.6% vs. 0.8%, p = 0.0003) and an adjusted OR of 15.9, 
95% CI, [3.5, 72.1].  For the second outcome, there was no significant statistical significance for 
new cancer screening test notices for those with an increased risk for hereditary cancer 
provided by health care providers between the intervention and control groups at eight vs. zero 
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provided respectively.  Participation in the post-appointment telephone survey was suboptimal 
with the intervention and control groups at 46.1% and 20.2% compliance respectively.  
Additional limitations of the study were: non-randomized groups, poor overall participation with 
only 10.3% of those eligible participating, differences in demographic characteristics between 
the two groups, and instrument reliability and validity was not provided.  Conclusions were 
based solidly on results, as use of this web-based risk evaluation tool demonstrated an overall 
increase in documentation of cancer family history.  Due to the lack of instrument reliability and 
validity, poor participant response rates, and potentially lacking the ability to generalize results 
related to demographic differences, this study was provided a quality rating of B.               
 Level III evidence.  The majority of evidence appraised was Level III evidence, with one 
each of the following: exploratory pilot study, demonstration project, qualitative study, 
systematic review of a combination of studies, and cross-sectional study.  Anderson et al. 
(2015) implemented an exploratory pilot study with low income African American and Hispanic 
women ages 25 to 69 years old, without a personal history of breast cancer, presenting for 
annual examinations at two federally assisted medical institutions in the Midwest.  The purpose 
of this study was to evaluate the development and utilization of a breast cancer risk appraisal 
policy within a practice with multiple ethnicities.  In a study population of N = 237, prior to 
examination with the health care provider, the following was collected: (a) risk factor information, 
(b) baseline survey, and for those consenting, (c) a breast cancer risk evaluation using the BC 
Risk Screening (BRS) web-based tool.  This tool simultaneously uses the following to provide a 
risk assessment: (1) Claus, (2) modified Gail, and (3) pedigree assessment tool.  The majority of 
the population (n = 207, 87.3%) chose to be informed of their breast cancer risk assessment 
results with an increased likelihood with women ages 40 to 49 years old with OR 5.4 (95% CI, 
[1.09, 26.67]) and from 50 to 69 years old with OR 7.99 (95% CI, [1.47 - 43.44]).  Successful 
use of a web-based tool in the office setting to efficiently perform the risk appraisal was 
evidenced by the high rate of BRS tool use noted in this population, with consideration of health 
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care provider barriers of time restraints and/or lack of breast cancer risk knowledge.  Limitations 
were the: (1) Inability to obtain additional explanations from the women who declined receiving 
their risk information; (2) potential lack of generalizability with women from other ethnic 
backgrounds; and (3) potential recruitment bias as women arriving for their annual examination 
presumably placed more of a priority on their health.  The researchers concluded that 
implementing a web-based tool, as recommended by the USPSTF 2013 recommendations, 
enhanced performance of a breast cancer risk appraisal in the office setting.  Furthermore, this 
process occurred without disturbance of the normal workflow in a primary care practice.  This 
exploratory pilot study was provided a quality rating of B due to the small sample size, omission 
of information regarding the reliability and validity of the BRS tool, and the potential limitation to 
generalize results to women of different ethnicities.         
  Brannon Trexler et al. (2014) demonstrated utility of the breast cancer genetics referral 
screening tool (B-RST™) through a demonstration project.  The sample population was 
primarily minority and low-income women ages 14 to 85 years old without a personal history of 
cancer obtaining health care at one of six participating public health departments in a southern 
U.S. state.  The participant population was adequate with N = 2159.  The staff was educated 
through multiple methods on hereditary breast and ovarian cancer (HBOC) syndrome and how 
to use the B-RST™.  In order to identify and manage appropriate at-risk women, the B-RST™ 
was then used during medical history collection prior to the health care provider examination.  
The objectives of this project were: (1) Integrating the B-RST™ within a minority population to 
recognize women with increased HBOC risk; (2) assisting with the health care management of 
those having positive B-RST™ results; and (3) educating staff about cancer genetic topics with 
the goal of accurate utilization of the B-RST™.  Validity of the B-RST™ occurred by comparing 
its use to multiple models with four-generation cancer family histories.  Sensitivity was 
determined to be 89.4% and specificity was 90.1%.  For the first objective, out of the 2159 
participants: (a) 130 (6.0%) had positive B-RST™ results, (b) 110 (84.6%) from this group of 
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women then consented to be contacted, (c) 67 (60.9%) provided cancer family history 
clarification, (d) 47 (42.7%) of these women were successfully contacted and determined to be 
appropriate for testing per current medical society guidelines, and (e) 14 (12.7%) performed 
cancer genetic testing, with one (7.1%) woman being diagnosed with a BRCA2 gene mutation.  
She was guided through medical management strategies, which then completed the second 
objective.  The third objective was achieved by an increase in staff knowledge as demonstrated 
by improved post-activity test results.  One of the limitations was that participants were not 
aware a multi-generational cancer family history was going to be requested at their 
appointment, with potential inaccuracies likely causing both false negative and false positive B-
RST™ results.   Also, the reason(s) why participants declined follow up (n = 20) after receiving 
positive B-RST™ results was not collected.  The researchers concluded that their project had 
favorable outcomes, especially with evaluation of breast cancer risk in a group of minority 
women who likely did not have this assessed before.  This study was given a quality rating of A 
for the large sample population, inclusion of the tool’s sensitivity and specificity, and conclusions 
based on EBP.      
  Christianson et al. (2012) presented their qualitative study of use of a risk assessment 
tool by health care providers from a variety of specialties within a community-based medical 
system on the East Coast.  The sample population (N = 16) consisted of 14 physicians and two 
mid-level providers from nine medical practices within the same county.  The demographics of 
the sample population were primarily males (n = 12) and Caucasians (n = 12).  This information 
was not provided for both of the mid-level providers.  The purpose of this study was to 
determine health care provider perceived challenges with integration of a risk stratification tool 
in order to resolve these factors and improve its future utilization.  The participants attended one 
of the three focus meetings in which nine questions were discussed regarding the impending 
use of the MeTree web-based risk assessment tool at a local oncology center.  This tool 
evaluates inherited risks for breast and colon cancers, in addition to thrombophilia disorders.  
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Five themes were recognized: (1) Current methods utilized for evaluating risk of medical 
conditions, (2) barriers associated with obtaining and using family health histories, (3) 
challenges associated with applying family history to individualized health care strategies, (4) 
obstacles with performance of the MeTree tool at the oncology center, and (5) medical and 
educational needs.  Although these themes were noted repetitively, the researchers reported 
that saturation was not attained related to the small sample population.  Validity and reliability 
were applied by performance of the following for both of the discussions: (a) use of a topic 
template guide, (b) being led by the same individual, (c) producing an audio recording, (d) 
obtaining written documentation including non-verbal elements, and (e) providing a manuscript 
from the audio recording.  For interpretation of the data, this information was coded and 
analyzed both manually and with the use of a computer software program.  It is unclear if there 
was a method used to verify the credibility of the data evaluation with this sample population.  
Considering the small sample size and subsequent lack of saturation, the quality rating of A/B 
was provided for the inclusion of distinct methods for supporting this qualitative study’s purpose 
and incorporating a perceptive analysis pertinent to available evidence. 
      Nelson et al. (2014) performed a systematic review of multiple study types as an update 
to the 2005 USPSTF recommendation for hereditary breast cancer risk evaluation and genetic 
services utilization.  The population of interest was women across the lifespan provided health 
care in locations similar to the U.S. without a personal history of a BRCA gene mutation or 
BRCA-related cancer(s).  For studies included in this review (N = 27), 16 were new for this 
update and included systematic reviews, RCTs, cohort, and case-control studies.  A variety of 
interventions were studied: (a) five risk models/tools; (b) risk perception and cancer worry; and 
(c) tests, meds, and surgeries to decrease risk of BRCA-related cancers.  The outcomes of 
concern evaluated potential benefits and harms in three areas: (1) BRCA risk evaluation 
model/tool use, (2) genetic services results, and (3) BRCA management options for malignancy 
and mortality reduction.  Outcomes were based on study findings with a best practice 
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recommendation presented to weigh individualized benefits, harms, and risks when assessing 
hereditary breast cancer risk, referring for genetic services, and/or offering medical 
management to decrease cancer risk.  Sensitivity between five referral and four risk models 
were compared with the Referral Screening Tool reported as having high levels of sensitivity 
and specificity.  Although the authors were unable to perform a quantitative meta-analysis due 
to study heterogeneity, this systematic review was rated at an A quality due to the search 
strategy and findings from this systematic review being comprehensive with outcomes based on 
EBP.    
  Solomon, Whitman, and Wood (2016) performed a cross-sectional study of women with 
an average age of 63 years old receiving services at a mammography center in a Northeastern 
U.S. city.  The sample population (N = 499) was sufficient.  A questionnaire was completed at 
the time of mammography services.  The recommendation for reviewing additional breast 
medical management options, such as genetics services referrals, were then based on the use 
of the: (1) ACS and NCCN screening guidelines for colon cancer, (2) Claus model for breast 
cancer risk estimation, and (3) breast cancer genetics referral screening tool (abbreviated RST 
by the authors).  This study’s aim was identification and comparison of individuals qualifying for 
cancer genetic services based on either a limited/first-degree cancer family history or a more 
comprehensive/first and second-degree family histories in order to determine appropriate 
candidates for genetic services referrals.  Out of the 499 participants: (a) 71.9% (N = 359) had a 
family history of breast or colon cancers in a minimum of one family member; (b) 56.5% (n = 
282) had a family history of breast cancer in a minimum of one family member; (c) 24.6% (n = 
123) had a family history of colon cancer in a minimum of one family member; and (d) 13.2% (n 
= 66) had a family history of both breast and colon cancers.  Based on cancer family history, the 
Claus Model and the RST were then performed to determine breast cancer risk, and ACS 
guidelines were applied to assess risk for colon cancer.  The Claus Model recognized 3.6% (n = 
18) as being at-risk for breast cancer; with only 28% (n = 5) of these 18 women classified at-risk 
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when the limited/first-degree cancer family history was taken into consideration.  Similar results 
were discovered using the RST, with 1.8% (n = 9) of the women being considered appropriate 
for genetic services referrals; out of these nine women 77% (n = 7) were identified as being 
candidates for genetic services referrals with use of the limited/first-degree cancer family 
history.  For the colon cancer risk evaluation, 12% (n = 62) qualified for increased risk screening 
procedures following ACS recommendations; whereas, 81% (n = 50) of the 62 women were 
recognized with limited/first-degree family history use.  Limitations of this cross-sectional study 
were that selection bias was a potential due to the location of a mammography facility for 
questionnaire distribution, the lack of a description of the model/tool reliability and validity, and 
data collection occurred > one decade prior (2001 through 2002).  The concluding factor drawn 
from this study highlighted the importance of using a risk screening tool, rather than exclusively 
reviewing first and second-degree cancer family history, in order to provide an accurate 
hereditary cancer risk evaluation.  With the limitations taken in consideration, this cross-
sectional study was provided a quality rating of B due to an adequate sample size and overall 
results applicable to practice.  
  Level IV evidence.  Appraisal of Level IV evidence consisted of one professional 
organization clinical practice guideline and one evidence summary.  Based on evidence-based 
research findings, Berliner, Fay, Cummings, Burnett, and Tillmanns (2013) updated the 2007 
National Society of Genetic Counselors (NSGC) clinical practice recommendations.  Evidence 
was included from multiple professional organizations with the majority of the studies and 
articles cited focusing on hereditary breast cancer risk assessment models and BRCA genetic 
mutations.  Six concise best practice recommendations were specified as follows: (1) Consult 
guidelines to determine if a woman is a candidate for cancer genetic testing and provide 
individualized health care risk-reducing strategies; (2) consider BRCA and other applicable gene 
mutations; (3) perform a cancer risk evaluation utilizing an assessment model to determine 
subsequent approach for health care management; (4) determine medical management options 
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based on cancer family history, assessed risk, medical expertise, and outcome of genetic 
testing; (5) arrange referral to a genetics professional to provide resources to support 
educational and emotional needs; and (6) explain current, multi-faceted consequences of 
genetic testing.  Each recommendation was supported by EBP.  This best practice guideline is 
both advantageous and easily applicable, with it being provided a quality rating of B due to the 
omission of information regarding biases and evidence levels, and related to it being a six year 
old guideline due to be updated.         
 Obeid (2017) authored a Joanna Briggs Institute Evidence Summary focused on familial 
breast cancer.  References used for this summary encompassed two Cochrane Database 
systematic reviews, evidence from the National Institute for Clinical Excellence, and one each of 
the following: meta-analysis, RCT, cross-sectional observational study, epidemiological study, 
and a literature review.  Regardless of practice specialty, this summary is applicable for any 
health care providers involved in primary, secondary, or tertiary care of women with a family 
history of breast cancer.  Best practice recommendations were specified for: (1) Patient-focused 
care; (2) cancer family history and provider referral; (3) screening; and, (4) genetic services.  
These were subsequently graded by the author, with each receiving a grade B.  Concise 
instructions for these best practice recommendations were provided.  Most pertinent to this EBP 
project were suggestions for: (a) promoting patient-provider discussion about breast cancer risk 
that respects a patient’s personal decisions; (b) creating and providing handouts on pertinent 
breast cancer risk topics; and, (c) producing protocols for performing genetic services referrals.  
A limitation was that information was not provided in regards to the process of reducing biases.  
This piece of evidence is rated as an A/high quality based on the up-to-date nature of the 
summary, the high levels of evidence used, and its broad applicability.    
 
 
 
HEREDITARY BREAST CANCER PROTOCOL 31 
 
 
Construction of Evidence-based Practice 
Synthesis of Critically Appraised Literature 
 Within the evidence, several challenges were presented with enhancing care by using a 
cancer risk evaluation model or tool.  It can be time consuming to accurately identify and 
reassure those at low risk for hereditary breast cancer, while informing those who are at-risk 
about medical management options and promoting active involvement in their health care 
(Anderson et al., 2015; Hilgart et al., 2012; Solomon et al., 2016).  The lack of importance 
individuals may perceive about their cancer family history, coupled with inaccuracies of 
reporting this history, may impede the accuracy of risk appraisal results and consequently the 
management of these results (Baer et al., 2013; Brannon Trexler et al., 2014).  Additional 
barriers of risk appraisal tool utilization consisted of: (a) time restraints; (b) health care provider 
knowledge and confidence limitations; (c) necessity for specific guidelines to direct care; (d) 
communication limitations; (e) legal responsibilities, and (f) resources restraints, including 
availability of health care providers to perform genetic counseling (Christianson et al., 2012).  
Another challenge encountered is the variance between different medical professional 
organization’s recommendations for qualifications for genetic services (Berliner et al., 2013).  
Although these differences may be minimal, they can create confusion and potentially a lack of 
consistency in this area of health care.  It is important to be knowledgeable about these factors 
in order to identify methods to overcome them.   
 Regardless of the type of model or tool utilized for the process of hereditary breast 
cancer risk evaluation, positive consequences for both health care providers and patients were 
reported.  A specific recommendation that guides the focus of this EBP project is presented by 
Berliner et al. (2013), which highlighted that health care providers have the flexibility and 
responsibility of choosing which risk appraisal tool is best for their practice.  A risk appraisal tool 
demonstrating ease of use was important for gaining health care provider support of its 
implementation into routine practice, while it enhanced more thorough documentation of cancer 
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family history, understanding of results, and conversations regarding this history (Anderson et 
al., 2015; Baer et al., 2013).  Use of the RST improved accuracy of identifying and appropriately 
educating individuals at-risk for hereditary breast cancer (Obeid, 2017; Solomon et al., 2016).  
Using a family history tool to assess cancer risks supported communication about these risks 
between the provider and a patient and consequently guided management options (Berliner et 
al., 2013; Christianson et al., 2012; Kaplan et al., 2014).  Beneficial outcomes of appropriate 
breast cancer risk evaluations include perceived individual benefits and enhanced satisfaction 
with counseling (Hilgart et al., 2012; Obeid, 2017) as well as decreased levels of worry after 
receiving genetic counseling (Nelson et al., 2014).  The evidence appraised extensively 
supports incorporating a hereditary breast cancer risk evaluation tool into health care practice.    
Best Practice Model Recommendation 
  The Best Practice Model for answering this EBP project’s PICOT statement was to have 
women perform a B-RST™ evaluation at their routine gynecological examination and/or new 
patient appointments within the Ob/Gyn practice.  This assessment occurred at the beginning of 
their appointment, prior to their health care provider seeing them.  The B-RST™ was chosen 
due to support provided by the USPSTF related to its ease of use by both patients and health 
care providers, in addition to having received the highest quality rating (Bellcross, Hermstad, 
Tallo, & Stanislaw, 2019; Nelson et al., 2019).  Furthermore, this tool was either utilized or 
evaluated in three of the pieces of evidence appraised with positive feedback regarding its use, 
in addition to high levels of sensitivity and specificity documented (Bellcross et al., 2019; 
Brannon Trexler et al., 2014; Nelson et al., 2014; Solomon et al., 2016).  The Best Practice 
Model with use of the B-RST™ helped answer this EBP project’s clinical question by providing a 
reliable and straightforward intervention for hereditary breast cancer risk assessment, data 
collection, and comparison to the current practice of cancer family history collection and review 
in the EMR.  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
 At the EBP project setting, the standard practice for establishing if a woman is 
considered at-risk for hereditary breast cancer is determined by reviewing the personal and 
family medical history sections in the EMR.  Prior to completing charting for a patient visit, the 
appropriate boxes are expected to be marked in the EMR indicating that specific sections (i.e., 
the history sections which include both personal and family medical histories) have been 
reviewed.  An underlying assumption in marking these areas of information as reviewed is that a 
woman at-risk for hereditary breast cancer is identified and counseled about associated risks 
and provided medical management options, with the necessary documentation indicating both 
these activities occurred.  In addition to the EMR review, select providers within the EBP project 
site have their patients complete a personal and cancer family history paper questionnaire, 
created by a company that performs cancer genetic analysis.  Although this is a method in 
which to identify women at increased risk for breast cancer, the intent of utilizing this form is for 
the health care provider to personally order genetic testing.  It is neither intended for the primary 
purpose of identifying women who are candidates for genetic counseling, nor is it amongst the 
tools evaluated and recommended by the USPSTF.  This lack of uniformity in screening patients 
in addition to the current use of tools unsupported by best practice reinforced the necessity for 
this EBP protocol to standardize screening women using a validated and efficient tool to 
effectively identify high-risk women who are candidates for genetic consultation. 
Participants and Setting 
 The participants for this EBP project included women 18 years or older who sought care 
for a routine gynecological examination or a new patient appointment at an Ob/Gyn practice.      
The sample population included pregnant women if they were new patients but excluded those 
who were established patients receiving continuation of obstetrical care.  Individuals with 
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impaired mental capacity either related to dementia or developmental conditions (e.g., mental 
retardation) were not offered to participate.  A personal history of breast cancer was not an 
exclusion factor.  If a woman returned to the office for repeat care during the project’s time 
frame, the screening tool was only utilized once unless a personal or familial cancer history 
change occurred.   
 The EBP project setting was comprised of five office branches of an Ob/Gyn practice 
located in two adjoining Northwest Indiana counties.  The practice is owned and operated by a 
hospital system, which is part of the largest health care system in this region.  The 
organization’s mission is “…to provide the highest quality care in the most cost-efficient manner, 
respecting the dignity of the individual, providing for the well-being of the community and serving 
the needs of all people, including the poor and disadvantaged” (Health Care System, nd).  The 
values of this health care system are community, compassionate care, dignity, quality, and 
stewardship (Health Care System, nd).  This proposed protocol embraces the mission and 
values of this health care system.   
 Three physicians, three NPs, and three CNMs are currently employed at this Ob/Gyn 
practice.  Each health care provider sees patients in a variety of the five office locations.  
Approximately 400 patient appointments occur weekly.  Both insured and uninsured patients are 
seen at this practice.  The types of insurance plans utilized comprise an extensive amount of 
commercial plans, Medicaid, and Medicare coverage.   
Pre-Intervention Group Characteristics 
 The geneticist employed by this health care system provides cancer genetic 
consultations at two nearby facilities.  Between July 1, 2018 to July 1, 2019, the nine health care 
providers at the Ob/Gyn practice referred 30 women for genetic services (H. Hendricks, 
personal communication, August 20, 2019).  This reported amount of referrals was likely lower 
than what actually occurred, as the health care provider may have initially given the geneticist’s 
contact information to the patient as they began considering participating in this medical 
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management option.  If this occurred and the patient then called to schedule a consultation 
without updating the health care provider, a formal referral was often missing from the EMR.  
Additionally, some of the providers often recommended a referral to this health care system’s 
High Risk Breast Clinic for additional breast cancer risk assessment to be performed first, at 
which time the routine practice was for genetic services to be reviewed and offered as 
appropriate (D. Faitek, personal communication, August 6, 2019).  Between the dates of July 1, 
2018 through July 1, 2019, a total of 38 referrals were placed to the High Risk Breast Clinic by 
the nine providers at this health care practice.   
Intervention 
 An evaluation of eight breast cancer risk appraisal tools was performed by the USPSTF, 
with two receiving a quality rating of good, to include the B-RST™ (Nelson et al., 2019).  The B-
RST™ was implemented in several research studies related to being straightforward and not 
time consuming to incorporate into practice (Cintolo-Gonzalez et al., 2017).  This web-based 
tool is freely accessible for use, with the request of crediting the developer for use in this EBP 
project, Dr. Cecelia Bellcross (C. Bellcross, personal communication, July 10, 2019).  Dr. 
Bellcross provided permission for a hyperlink to the B-RST™ to be accessible within the EBP 
project site’s EMR (see Appendix D).  Due to being amongst the appraisal tools recommended 
by the USPSTF and its reported ease of use, the B-RST™ was chosen to screen and identify 
women at-risk for hereditary breast cancer.   
 Upon arrival at the office and being greeted by the registration representative, women 
signed in for their appointment and were either provided a pen and customary paperwork or the 
tablet to complete the check in process.  Next, the patient was called back by the MA to 
complete vital sign assessments as well as a review of history information within the EMR.  
During this process, the MA accessed the B-RST™ hyperlink within the flowsheet section of the 
EMR and completed this assessment with the patient.  The risk evaluation result (negative-
average, negative-moderate, or positive-high) was entered in the flowsheet section by the MA 
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for the health care provider to review; in addition, the risk level was marked on the front of the 
patient results handout created by the DNP student entitled, Understanding Your Breast Cancer 
Genetics Referral Screening Tool (B-RST™) Results (see Appendices E and F).  This one page 
handout was then placed in the plastic folder that contained a form listing the patient’s name, 
date of birth, reason for appointment, and additional patient specific components requested by 
each health care provider.  After the MA completed the rooming process, this plastic folder was 
either placed in a rack outside of the patient’s examination room or given directly to the provider.  
The women were then seen by their health care provider as scheduled.  The provider reviewed 
and discussed the B-RST™ risk results with the patient and subsequently provided the handout 
to the patient.  These handouts were adequately supplied at each of the offices at the initiation 
of the project and then provided to the managers and/or personally delivered to each of the 
office locations as needed to ensure the supplies remained adequate.  For those women with 
negative-moderate or positive-high risk B-RST™ results, their appointment records were 
reviewed approximately ten weeks afterwards to verify if a consultation appointment was made 
and kept at the High Risk Breast Clinic and/or with the geneticist.  Appointments were verified 
for the final time on March 1, 2020.    
 The DNP student ran a weekly report through the Epic EMR to gather data on the 
following information:  (a) participant initials and medical record number, (b) demographics, 
which included age, race, insurance type, and religious preference, (c) appointment type, and 
(d) B-RST™ results.  In addition, each provider’s daily schedule was evaluated in the EMR for:   
(a) candidates eligible for the protocol, (b) B-RST™ performance without results entered in the 
flowsheet, (c) B-RST™ performance without qualifying for the protocol, (d) eligibility for a 
referral to the High Risk Breast Clinic and/or geneticist, (e) referral provided to the High Risk 
Breast Clinic and/or genetic counseling, (f) referral documented but not actually ordered, and (g) 
documentation if a referral was declined or had been performed previously.  The preceding 
information was recorded in an Excel EBP data spreadsheet that was organized by both the 
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week of the project and the provider.  Printed copies of the weekly reports were kept in a locked 
cabinet at the Ob/Gyn office and/or safely secured in a closet at the DNP student’s place of 
residence.  These reports will be shred upon completion of this EBP project and the Excel files 
will be permanently deleted from the DNP student’s home desk top computer.   
  Planning.  As delineated in chapter two, use of the seven steps of the Iowa Model 
provided guidance for the development and implementation of this EBP project.  Steps one and 
two were achieved with the decision to pursue the EBP topic of hereditary breast cancer 
assessment, along with the establishment of the PICOT directing the focus of evaluating risk for 
identifying appropriate candidates for genetic services referrals.  Nearly all staff members at this 
Ob/Gyn practice were part of the EBP project team; however, during step three, key team 
leaders were identified based on their strengths and heightened interest in this project.  The key 
team leaders were primarily MAs assigned to work with a specific provider.  In accordance with 
this step, the protocol process and utilization of the B-RST™ was reviewed with the staff and 
their concerns, questions, and recommendations were considered and discussed.   Handouts 
delineating the process and responsibilities of the health care providers and MAs were provided 
and reviewed prior to the EBP protocol implementations (see Appendices G and H).    
 Step four of the EBP process was completed prior to protocol implementation, 
encompassing a comprehensive review of the literature. A total of ten pieces of evidence were 
appraised and utilized to support the EBP project and the proposed protocol.  Meanwhile, the 
fourth step was accomplished by choosing a tool with simple features allowing the staff to obtain 
and review results promptly, with the goal of performing an accurate hereditary breast cancer 
risk assessment while limiting interference with the normal daily office routine.   
 For step five, the EBP protocol was implemented, with the steps detailed in the 
preceding section entitled “Intervention.”  Two weeks into EBP protocol implementation, initial 
data and feedback from stakeholders was reviewed and analyzed, which guided the project 
manager to make adjustments as necessary to continue this process.  Health care provider 
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compliance was considered adequate if appropriate use of the tool occurred with at least 75% of 
the women who qualified for the protocol.  In order to either maintain or improve participation 
rate, challenges specific to protocol adherence were discussed with appropriate team members.  
Individual compliance rates were calculated weekly by comparing the number of patients eligible 
for use of the B-RST™ with those who actually had the tool performed and documented.  The 
trial portion of this fifth step was an integral part of the process towards achieving favorable EBP 
practice model adherence.  With the exception of some providers requesting their patients to be 
given their results handout prior to them entering the room, it was determined during the pilot 
portion that the remaining ten weeks of the EBP project would be completed as initially planned. 
 During step six, integration of the B-RST™ in this health care setting was determined to 
be a proficient method for identification and referral of women at-risk for hereditary breast 
cancer in this health care setting.  Necessary strategies for advancing beyond this step 
incorporated both education about this risk assessment tool and reinforcement of its use to 
ensure that changes remain long standing.  Consequently, the DNP student will consider 
completing the inquiry process required for adopting this tool as a health care system-wide EMR 
“best practice alert,” which serves as a reminder to health care providers to perform and/or 
review a specific task.  Step seven involved informing the staff about the progress and results of 
the protocol implementation.  Team members were incentivized for their participation throughout 
the project with a gift card drawing every two to three weeks.  Using the Iowa Model for this EBP 
project guided a successful change implementation and fostered a positive learning experience. 
 Data measures.  The B-RST™ evaluates if an individual is at increased risk for having a 
BRCA genetic mutation, which assists in determining which individuals are appropriate 
candidate for receiving a referral for genetic counseling with possible testing (Bellcross et al., 
2019; Cintolo-Gonzalez et al., 2017).  Developed in 2007 by Dr. Cecelia Bellcross, its original 
form was a paper questionnaire, named the Referral Screening Tool or RST.  The current 
version of this tool, B-RST™ Version 3.1, is internet-accessible and available to health care 
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providers and the public (Bellcross et al., 2019).  Emory University owns the rights to this tool 
(A. Kerber, personal communication, July, 12, 2018).  This tool has been recommended by the 
USPSTF since 2013 and is credited for its ease of use (Bellcross et al., 2019; Cintolo-Gonzalez 
et al., 2017; Nelson et al., 2019).  The B-RST™ has been utilized in a variety of studies and 
supported in many professional articles (Brannon Trexler et al., 2014; Paris et al., 2016; Pruthi, 
Heisey, & Bevers, 2015; Solomon et al., 2016; Stewart et al., 2016; Wernke, Bellcross, Gabram, 
Ali, & Stanislaw, 2019).    
 The B-RST™ is recognized for its straightforward use along with being highly validated 
(Cintolo-Gonzalez et al., 2017).  In 2010, the tool was advanced to the initial web-based B-
RST™ Version 2.0, with a sensitivity of 89.4% and a specificity of 91.5% overall with validation 
against the Family History Assessment Tool, Myriad II, and a cancer family pedigree including 
four generations; and when compared to the BRCAPRO and BOADICEA risk prediction models, 
the sensitivity increased to 100% (Bellcross et al., 2019).  Through a retrospective chart review 
(N = 277), validation of B-RST™ Version 3.0 against B-RST™ Version 2.0 was reported to have 
an increased sensitivity respectively (94.0% vs. 71.1%, CI 95%, p < 0.0001), but a decreased 
specificity respectively (29.4% vs. 53.1%, CI 95%, p < 0.0001); the authors reported despite the 
reduction in specificity, those with positive risk results were verified to be candidates for genetic 
services referrals (Bellcross et al., 2019).  A two-sided McNemar’s Chi-square test was used for 
comparison of sensitivity and specificity of these versions (Bellcross et al., 2019). 
 Bellcross et al. (2019) differentiated between the following categories of B-RST™ risk 
results: (1) Negative-average, (2) negative-moderate, and (3) positive.  Negative-average risk 
results reveal the possibility of that individual having a BRCA gene mutation is highly 
improbable and the risk for breast cancer is that of the average population.  Negative-moderate 
risk results demonstrate the possibility of that individual having a BRCA gene mutation is low, 
but risk for breast and/or ovarian cancer is elevated.  Positive risk results signify the possibility 
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of that individual having a BRCA gene mutation is increased by at least 5-10%, with subsequent 
increased risks for breast, ovarian, and other BRCA-related cancers. 
 B-RST™ results were reviewed by the health care provider during the appointment.  The 
women who had negative-average risk results who were 40 years or older had a mammogram 
ordered if due for this test and per the health care provider’s recommendations.  Those whose 
results were negative-moderate risk have an increased risk for breast cancer, but are not likely 
at risk for a hereditary BRCA gene mutation.  In addition to having a mammogram ordered for 
those with negative-moderate risk results for those who were 40 years or older and due for this 
test, they were also candidates for a referral to the health care system’s High Risk Breast Clinic.  
The women who had positive risk results were determined to be at an increased risk for a BRCA 
gene mutation.  Management recommendations included a mammogram ordered for those 40 
years or older and due for this test, in conjunction with offering referrals to both the High Risk 
Breast Clinic and for genetic services with the health care system’s local geneticist.   
 Collection.  Data collection for analysis included completing the B-RST™, recording 
these results in the EMR flowsheet, and ordering consultation referrals.  The first two steps were 
completed by the MA and the last step was the responsibility of the health care provider.  The 
Epic information technologist initially assisted the DNP student with the process of creating 
parameters and then running reports once weekly to obtain relevant data.  Each provider’s daily 
schedule was reviewed to verify eligible patients, referrals ordered, and evaluate 
documentation.  Chart audits occurred at appropriate intervals to verify if a participant had 
scheduled, cancelled, rescheduled, or attended a consultation at the HRBC and/or for genetic 
counseling.  This data was then entered in the Excel EBP project data spreadsheet.  
 Management and analysis.  Health care provider protocol adherence and post-referral 
genetics and/or High Risk Breast Clinic consultation participation rates were evaluated.  
Protocol adherence was determined if there was documentation of the B-RST™ results in the 
flowsheet section of the EMR and subsequent referrals provided to those with negative-
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moderate or positive-high risk results.  High Risk Breast Clinic and genetics consultations had to 
be completed by March 1, 2020 to be included in the analysis of this EBP project.  
 Descriptive statistics were utilized to specify participant demographics.  The Chi-square 
test for independence was used to determine if the pre- and post-implementation groups were 
independent of each other.  Factorial ANOVA analyses were performed to determine if use of 
the B-RST™ affected the health care providers ordering HRBC and/or genetics referrals in 
comparison to the referral ordering practices for the pre-implementation group. 
Comparison 
 One year prior to the protocol implementation, from September 24, 2018 through 
December 14, 2018, eight women were provided referrals by the nine health care providers in 
this practice to the local geneticist for counseling regarding their cancer family history.  During 
this same time frame, six women were referred to the High Risk Breast Clinic for management 
of their increased risk for breast cancer.  Use of the B-RST™ assisted in identification of 
additional women at-risk for hereditary breast cancer who were then able to pursue additional 
medical management options appropriate for this risk.  Based on the use of this risk evaluation 
tool, there was an increase in both referrals for genetic services and to the High Risk Breast 
Clinic. 
Outcomes 
  The primary outcomes of interest were the number of participants with negative-
moderate or positive-high risk results and subsequently the amount of HRBC and genetics 
referrals provided to these individuals.  Consistent with the appraised literature supporting this 
best practice protocol, it was anticipated that compared to simply reviewing family history in the 
EMR, use of the B-RST™ would increase health care provider identification and referral of 
women at-risk for hereditary breast cancer.  Secondary outcomes included data regarding the 
participant rates for HRBC and/or genetics consultation performance.  In addition, the health 
care provider protocol participation in regards to referrals ordered.  Although it was suspected 
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differences would be noted between adherence rates for the APRNs and physicians within this 
group, participation will be ascertained for the entire Ob/Gyn practice as an aggregate.    
Time 
 Approximately two months prior to implementing the protocol, each of the health care 
providers at the Ob/Gyn office and the geneticist were recruited.  Next, the DNP student trained 
the medical assistants individually how to use the B-RST™.  Protocol details were reviewed, 
including who qualified for use of the tool and how to document these results.  The EBP project 
was implemented for twelve weeks, starting September 23, 2019 and ending on December 13, 
2019.  Genetic and/or High Risk Breast Clinic consultation participation was verified by March 1, 
2020.   
Protection of Human Subjects 
 It is imperative during the pursuit of advancing health care knowledge that the rights of 
individuals are protected.  Key ethical aspects prioritized during the development and 
implementation of this EBP project were autonomy, beneficence/nonmaleficence, and justice.  
An objective throughout this project was to provide consistent and comprehensive care to 
women in adherence with the identified best practice standards.  Patients were assessed using 
the B-RST™ as long as the inclusion factors were met.  In meeting ethical course requirements 
prior to the study’s initiation, the NIH ethics web-based course entitled “Protecting Human 
Research Participants” was completed on April 5, 2018 (Certificate Number 2628916).  This 
EBP project was found to be classified within the exempt non-research category and therefore 
did not require further review from the Institutional Review Board (IRB) at Valparaiso University.  
The EBP project was then reviewed and approved by the IRB at the health care system at 
which it was performed (see Appendix I).  
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CHAPTER 4 
FINDINGS 
The purpose of this EBP project was to determine if utilization of the B-RST™ risk 
assessment at a nine provider Ob/Gyn practice in a Midwestern state was an effective process 
for identifying women at-risk for hereditary breast cancer for the purpose of providing High Risk 
Breast Clinic (HRBC) and/or genetic counseling referrals.  Pre-implementation (before protocol 
intervention) and post-implementation (after protocol intervention) data were compared in this 
project.  The pre-implementation group was comprised from a chart audit and included 880 
patients who were seen one year prior.  Data were collected from electronic medical records by 
process of entering B-RST™ results in the EMR, reviewing populated EMR reports, and 
performing chart audits for the post-implementation group.  A total of 994 women had the B-
RST™ assessment completed during routine gynecological and new patient appointments 
during this 12-week EBP project.   
Participants 
Pre-implementation Demographics 
 Demographics information was collected through an EMR chart review between the 
dates of September 24, 2018 through December 14, 2018, with this range being the same 12-
week time frame that the EBP project was implemented in 2019.  Demographic information for 
this population included: age, appointment type, insurance coverage, race, and religious 
preference.  The EMR chart audit report that populated was unable to distinguish between 
appointments or encounter types.  Encounter types included patient-focused activities such as: 
clinical updates, email messages, registration for tests (labs, mammogram, etc.), or 
incoming/outgoing telephone calls.  From the 4,181 appointments/encounters during this time 
frame, every third patient chart was audited to determine if the inclusion criteria were met 
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consisting of being ≥ 18 years old and seen for either an annual gynecological or new patient 
appointment, which subsequently resulted in a total of 880 patients.   
 The mean age of the patients in the pre-implementation group was 44.89 (SD = 14.361), 
with the ages varying from 18 to 83 years old.  On average, these patients were ≥ 40 years old 
(n = 607, 61.1%) and presented for routine gynecological examinations (n = 659, 74.9%).  In 
this group, the majority had commercial insurance (n = 669, 76.0%), were Caucasian or white (n 
= 747, 84.9%), and Christian (n = 458, 52.0%). 
Post-implementation Demographics 
 Information regarding demographics was obtained by running weekly EMR reports and 
was determined to be consistent with those in the pre-implementation group.  The ages of the 
post-implementation group participants ranged from 18 to 91, with a mean age of 44.87 and a 
SD = 14.337.  Most participants (n = 748, 75.3%) were over the age of 18 and were seen for 
routine gynecological examinations (n = 748, 75.3%).  Overall, they predominantly had 
commercial insurance (n = 795, 80.0%), were Caucasian or white (n = 861, 86.6%), and listed 
their religious preference as Christian (n = 517, 52.0%).   See Table 4.1 for additional 
demographic data delineation and comparisons between the pre- and post-implementation 
groups. 
Changes in Outcomes 
           Nearly seventy-five percent (n = 745, 74.9%) of the participants had negative-average 
risk B-RST™ results.  The remaining quarter of the group had negative-moderate (n = 75, 7.5%) 
and positive-high (n = 174, 17.5%) risk results (see Figure 4.1).  This data is consistent with the 
evidence from the literature.  In a study performed by Wernke et al. (2019), 72.2% of the 
participants had negative-average results, 9.5% had negative-moderate, and 18.3% were 
positive.  Per the protocol, 249 participants were eligible for a HRBC consultation and 174 for 
genetics.  Data for pre-and post-implementation HRBC and genetics referrals are to follow. 
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Pre-implementation HRBC and Genetics Referrals 
  The nine health care providers at this EBP project site consisted of three each of CNMs, 
NPs, and physicians.  Two of the three physicians had a NP that shares patients from their 
schedule.  The 994 participants screened with the B-RST™ saw the providers as follows: CNM 
(n = 210, 21.1%), NP (n = 244, 24.5%), physician (n = 347, 34.9%), and physician/NP (n = 193, 
19.4%).  Pre-implementation HRBC and genetics referral totals from these providers were 
determined through an EMR chart audit for this same 12-week duration one year prior and 
included HRBC (N = 6) and genetics (N = 8).  For the HRBC referrals, five (83.3%) were from 
the physicians/NPs and the remaining one (16.7%) was provided by a CNM.  Two (25%) of the 
genetics referrals were from the physician/NP and the remaining six (75%) were from the NP.  
Two of the six HRBC consultations were performed, whereas three of the eight genetic referrals 
were completed.  See Table 4.2 and Figure 4.2 for comparisons of pre- and post-
implementation HRBC and genetics referrals provided.        
Post-implementation High Risk Breast Clinic Referrals 
 In comparison to the pre-implementation group, the total referrals to the HRBC 
increased by 51.  Amongst the 249 participants who qualified for a HRBC referral, n = 57 
(22.9%) accepted this referral and n = 144 (57.8%) either declined or were not offered this 
option.  Of note, the majority of participants who were eligible for genetic counseling also 
qualified for a consultation at the HRBC.  An exception to this was individuals with a family 
history of ovarian cancer, but without any family members with a history of breast cancer.    
From the 57 HRBC referrals ordered, 30 (52.6%) were from the physicians/NPs, 19 (33.3%) 
from the NP, six (10.5%) from the CNMs, and two (3.5%) from the physician.   
 Documentation was reviewed in the EMR with the health care providers having reported 
that the HRBC referral was unnecessary for 31 participants (12.5%) or that the referral was 
ordered when in actuality this did not occur (n = 17, 6.8%).  The providers documented a 
discussion with a HRBC eligible participant 62.7% (n = 156) of the time.  If a patient declined the 
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referral, this was documented 58.6% of the time.  It was noted that 10 patients had a prior 
history of completing a consultation at the HRBC.  See Table 4.2 and Figure 4.2 for 
comparisons of pre- and post-implementation HRBC and genetics referrals.   
Post-implementation Genetics Referrals 
 Genetics referral totals increased by 24 with the post-implementation group.  A total of 
174 participants qualified for a referral for genetic counseling, in which n = 32 (18.4%) accepted 
this referral and n = 124 (71.3%) declined or were not offered this option.  The physicians/NPs 
ordered 16 (50%) of these referrals, with nine (28.1%) from the NP, six (18.8%) from a CNM, 
and one (3.1%) from the physician.  Within eligible participants, the health care providers 
documented that the genetics referral was unnecessary for three (1.7%) participants or that the 
referral was ordered when in actuality this did not occur (n =15, 8.6%).  Documentation of a 
discussion with a participant eligible for a genetics consultation was present 54.6% (n = 95) of 
the time.  If a participant declined the referral, this was documented 40.2% (n = 70) of the time.  
A total of 21 participants were noted to have a history of genetic counseling and/or testing 
performance.  See Table 4.2 and Figure 4.2 for comparisons of pre- and post-implementation 
HRBC and genetics referrals provided. 
Statistical Testing and Significance 
 IBM SPSS Statistics Standard Edition version 25 was utilized for variable and data entry, 
in addition to statistical analysis performance.  Frequencies were determined for pre- and post-
implementation participant demographics, B-RST™ results, referrals provided, and referrals 
completed (see Tables 4.1- 4.4 and Figures 4.1- 4.4).  The Chi-square test for independence 
was used to determine if the pre- and post-implementation groups were independent of each 
other.  A factorial ANOVA was performed to examine if there was a statistically significant 
difference between HRBC and/or genetics counseling referrals being provided pre- and post-
implementation in comparison amongst the health care providers at the Ob/Gyn practice.   
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 Chi-square testing.  The Chi-square test is a nonparametric level of analysis that 
utilizes nominal or ordinal data to distinguish if groups are similar or different, for the purpose of 
assisting with determining whether an intervention caused a change versus differences between 
a variable being the reason (Peters, Schmidt, & Fearncombe, 2015).  The Chi-square test for 
independence was used to distinguish if the demographic variables of age, appointment type, 
insurance coverage, race, and religious preference were statistically significant, or independent, 
between the pre- and post-implementation groups.  Statistical significance for all analysis was 
established as p < .05. 
 A chi-square test for independence was conducted comparing the demographic data of 
the pre- and post-implementation groups. There was no statistically significant difference found 
between these two groups on age (p = .946), appointment type (p = .855), insurance type (p = 
.054), race (p = .662), and religious preference (p = .421). Subsequently, the patients included 
in this sampling were considered to be representative of the patients seeking care in this 
Ob/Gyn practice. 
 ANOVA testing.  Verifying whether the means of groups vary is achieved through 
ANOVA (analysis of variance) testing; this can occur for multiple means and assists with type 1 
error minimization (Peters, Schmidt, & Fearncombe, 2015).  Between-subjects factorial ANOVA 
tests (hereafter referred to as ANOVA) were conducted with the independent variables of HRBC 
referral provided or genetics referral provided with the dependent variables of health care 
provider and pre- and post-implementation groups.  Statistical significance for all analysis was 
established as p < .05 and confidence intervals were 95.0%.  See Table 4.4 for ANOVA results.  
 The ANOVA test was performed to ascertain if being provided a referral for HRBC 
counseling varied with the health care providers at the EBP project site and the two groups (pre- 
and post-implementation).  Statistically significant differences were found for the group means 
of the health care providers (F(6, 1860) = 9.24, p < .001), the pre- and post-implementation 
groups (F(1, 1860), = 22.01, p < .001), and lastly the interaction effect between the providers 
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and these two groups (F(6, 1860), = 9.23, p < .001).  Therefore, the null hypothesis was 
rejected as these results indicated that the differences amongst the health care providers and 
between being in the pre- or post-implementation group affected the ordering of HRBC referrals.   
 The ANOVA test was then conducted to establish whether genetics referrals being 
ordered differed between the health care providers and the two groups (pre- and post-
implementation).  Statistically significant differences were found for the group means with the 
health care providers (F(6, 1860) = 5.36, p < .001), the pre- and post-implementation group 
(F(1, 1860) = 10.14, p < .001), and the interaction effect between the providers and the groups 
(F(6, 1860) = 6.46, p < .001).  Similar to the HRBC referrals, genetic referral provision 
differences were noted between the health care providers and the pre- and post-implementation 
groups.  
 Post hoc testing.  Since the above ANOVA results were statistically significant, post 
hoc testing was required to determine where the differences occurred within the health care 
providers ordering HRBC and genetics referrals.  With multiple types to choose from, Tukey 
HSD was selected (Cronk, 2018).  The Tukey post hoc test was not performed for the pre- and 
post-implementation groups related to no additional variable being available for comparison.  
The mean difference was significant at the p < .05 level.  
 Between the seven provider/groups previously delineated, 21 pairs of analyses 
occurred.  For the purpose of analyzing and interpreting the results from these pairs, 
physician/NP was categorized as physician1/NP1 or physician2/NP2.  CNM1, CNM2, and 
CNM3 differentiated between the three CNMs.  The remaining physician and NP were listed as 
such.   
 Statistical significance was noted, indicating that the following eight pairs of providers 
were statistically different from each other in regards to providing HRBC referrals: (1) 
physician1/ NP1 and physician2/NP2, (2) physician1/NP1 and the physician, (4) physician1/NP1 
and the NP, (5) physician1/NP1 and CNM1, (6) physician1/NP1 and CNM2, (7) physician1/NP1 
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and CNM3, and (8) the physician and the NP.  Regarding providing genetics referrals, the 
following three pairs of providers were statistically different from one another: (1) Physician 
1/NP1 and the physician, (2) physician1/NP1 and the NP, and physician 1/NP1 and CNM2.  The 
remaining pairs for both of these Tukey post hoc tests were not found to be statistically different.            
Findings 
 Primary outcomes.  The primary outcomes were the identification and referral of 
women considered to be at increased risk for hereditary breast cancer through a B-RST™ 
assessment.  During the 12-week EBP protocol implementation, 1253 women were eligible to 
have the B-RST™ performed at their appointments and this successfully occurred for 994 
participants.  At the onset of this EBP project, the minimum goal was set at 75% protocol 
adherence rate.  At its completion, the protocol participation rate was 79.3%.   
 Whereas 75% (n = 745) of the participants had negative-average risk results, 75 (7.5%) 
had negative-moderate risk results, and the remaining 174 (17.5%) were in the positive-high risk 
category.  As aforementioned, the majority of participants who were eligible for genetic 
counseling also qualified for a consultation at the HRBC.  Fifty-seven participants were provided 
a referral to the HRBC from the 249 who qualified.  Amongst the 174 participants who were 
eligible, 32 patients (18.4%) received referrals for genetic counseling.   
            Secondary outcomes.  Secondary outcomes included participant HRBC and/or 
genetics consultation participation rates.  Eight patients (14.0%) completed a HRBC 
consultation by March 1, 2020, with an additional six patients (10.5%) having upcoming 
appointments scheduled beyond this date (see Table 4.3 and Figure 4.3).  Appointments were 
scheduled at the HRBC and then either cancelled or not attended by nine participants (15.8%).  
Nearly 60% (n = 34, 59.6%) of those eligible had not yet scheduled a consultation at the HRBC.  
Genetic counseling appointments were completed by seven (21.9%) participants by March 1, 
2020, without any further appointments scheduled (see Table 4.3 and Figure 4.4).  Three 
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participants (9.4%) scheduled appointments and then did not attend or cancelled.  A total of n = 
22 (68.8%) had not scheduled an appointment yet.    
 Although the total HRBC and genetics referrals varied amongst the health care 
providers, this Ob/Gyn group as a whole ordered more of both of these during the post-
implementation in comparison to the pre-implementation time period (See Table 4.2 and Figure 
4.2).  The total combined HRBC and genetics referrals provided in the pre-implementation 
group were 14 and this increased to 89 in the post-implementation group.  Four of the providers 
did not provide HRBC referrals to the pre-implementation group, which decreased to one 
provider during the post-implementation.  Five of the providers did not provide pre-
implementation genetics referrals and two providers maintained this status post-implementation.      
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Table 4.1 
Pre- and Post-Implementation Demographic Comparison 
____________________________________________________________________ 
                   Pre-implementation Post-Implementation 
Totals                         n            %                  n               % 
____________________________________________________________________ 
Group  (N)                     880     994   
 
Age (mean, SD)               45         14.361      45              14.337                      
                                 
 
Appointment Type 
  Routine Annual Exam        659 74.9    748  75.3      
  New Patient          221 25.1                   246               24.7 
 
Insurance Coverage 
  Commercial         669 76.0               795  80.0 
  Medicaid                                     112 12.7    107                10.8 
  Medicare                                       91 10.3                     90    9.1 
  Uninsured                                       8   0.9                       2                 0.2 
 
Race 
  Caucasian or White                     747 84.9                 861  86.6 
  Other              71   8.0        63                6.3 
  African American or Black           62   7.0           70                7.0 
    
Religious Preference 
  Christian          458 52.0                517  52.0             
  No preference/none                    372           42.3                    431              43.4 
  Other             48   5.5                      41    4.1 
  Jewish                                             2   0.2                    5    0.5 
____________________________________________________________________ 
 
Note. Other category for race included: Asian, Native American, and unspecified.   
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Table 4.2   
Pre- and Post-Implementation Referral Comparison 
___________________________________________________________ 
              Pre-implementation   Post-implementation 
Totals                    n       n 
___________________________________________________________ 
 
Participants (N)              880               994      
 
Referral Provided 
  High Risk Breast Clinic                 6      57      
  Genetics        8      32      
       
Referral Performed               
  High Risk Breast Clinic      2        8 
  Genetics        3                                  7 
 
___________________________________________________________  
Note. Pre-implementation participants consisted of patients seen by the  
nine health care providers for annual exam and new patient appointments  
during the same 12-week time frame one year prior. 
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Table 4.3   
Post-Implementation Referral Eligibility, Provision, and Performance 
______________________________________________________________________ 
Referral Type            High Risk Breast Clinic   ___Genetics_____ 
Frequency, Total     n    %    n    %   
______________________________________________________________________ 
 
Eligible for Referral    249  25.1  174  17.5  
 
Referral Provided 
   Yes       57  22.9    32  18.4  
   No     144  57.8  124  71.3 
   Documented, but not ordered           17     6.8               15    8.6 
   Documented as unnecessary   31  12.4      3    1.7 
       
Referral Performed 
   Yes         8  14.0      7  21.9  
   No       34  59.6                 22  68.8 
   Currently scheduled      6             10.5      0       0   
   Scheduled, then cancelled      9  15.8      3    9.4 
______________________________________________________________________  
Note. Eligibility results from the total participants (N = 994) who had the B-RST™  
performed.  Participants with positive-high risk results qualified for referrals to HRBC  
and genetics. 
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Table 4.4   
Factorial ANOVA Results 
_______________________________________________________ 
      df  F value p value    
          (effect, error)  
_______________________________________________________ 
 
HRBC Referral     
  Provider        6, 1860  9.24  <.001           
  Group        1, 1860  2.01  <.001           
  Provider & Group         6, 1860  9.23  <.001           
 
Genetics Referral 
  Provider        6, 1860  5.36  <.001           
  Group        1, 1860               10.14  <.001           
  Provider & Group          6, 1860  6.46  <.001           
_______________________________________________________ 
Note. Statistical significance at p < .05  
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Figure 4.1 
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Figure 4.2   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HEREDITARY BREAST CANCER PROTOCOL 57 
 
 
Figure 4.3  
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Figure 4.4 
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CHAPTER 5 
DISCUSSION 
 The primary objective of this EBP project was to answer the following PICOT question:  
In women cared for in an obstetrical and gynecological practice, how does utilization of a breast 
cancer genetics referral screening tool, as compared to the current standard of care of collecting 
and reviewing family history in patients’ electronic medical record, allow women at increased 
risk for hereditary breast cancer to be appropriately identified and referred for genetic 
counseling within a twelve-week time frame?  Upon completing data analysis, statistically and 
clinically significant results supported the utilization of the protocol and assessment tool in this 
office setting.  The Iowa Model was an effective approach to guiding this change.  Knowledge of 
both the strengths and limitations with this EBP project can promote improvements and 
sustainability of B-RST™ use as a standard practice of care.  Recommendations focus on 
improving adherence to utilization of the B-RST™ assessment, in addition to enhancing patient 
participation in referral performance, in order to facilitate medical management in women at-risk 
for hereditary breast cancer. 
Explanation of Findings 
 During the 12 weeks that the EBP project occurred at the nine provider Ob/Gyn practice, 
1253 patients were candidates for having the B-RST™ assessment completed at their routine 
gynecological or new patient appointment.  The B-RST™ was successfully completed for 994 
(79.3%) participants, which achieved the goal of a minimum of 75% B-RST™ performance.  
With 75% (n = 745) of the B-RST™ results being negative-average risk, the remaining 25% (n = 
249) of participants were subsequently eligible for referrals to further assess and manage their 
elevated risk for breast cancer.  Per the EBP protocol, participants with negative-moderate risk 
results were to be offered referrals to the HRBC and those with positive-high risk results to both 
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the HRBC and genetics.  This resulted in 249 participants being candidates for consultations at 
the HRBC and 174 for genetic counseling.   
Participants 
 Pre-implementation data were obtained for the same 12-week time period one year prior 
to the protocol being implemented.  This group consisted of 880 patients.  The post-
implementation group included 994 participants.  Both of these groups were adequate in size.  
The average ages were nearly identical at 44.89 (SD = 14.361) and 44.87 (SD = 14.337) for the 
pre- and post-implementation groups respectively.  For each of these groups, the patients were 
predominantly Caucasian or white, Christian, had commercial insurance, and presented for a 
routine gynecological examination.  Although the results from this EBP project may be limited in 
generalizability related to this population not being diverse, Chi-square test for independence 
results were not statistically significant (p > .05), which indicated that the pre- and post-
implementation groups were a representative sampling of the patients seeking care at this EBP 
project site.  This information assisted in the further determination that the protocol 
implementation likely supported the results noted, instead of differences between the 
demographic variables amongst these two groups.   
High Risk Breast Clinic Referral Candidates and Referrals Provided 
 Following the EBP protocol, participants with negative-moderate (n = 75, 7.5%) and 
positive-high (n = 174, 17.5%) risk results met the qualifications for receiving referrals to the 
HRBC.  An exception to this was participants who had a family history of ovarian cancer, but 
without an incidence of breast cancer, which would slightly decrease the total participants 
eligible for the HRBC.  Related to potential inaccuracies in participants’ family medical history 
and/or if this information was not documented by the health care provider, this exclusion was 
not omitted from the total.  From these 249 participants, HRBC referrals were provided to 57 
(22.9%) and completed by 8 (14.0%) participants.  In comparison, six referrals were ordered for 
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the pre-implementation group, with an improvement by nearly ten-fold (n = 51) during the 12 
weeks the EBP protocol was implemented.   
 Nine HRBC appointments were scheduled and then either not attended or cancelled.  In 
addition, six appointments remain scheduled, but had not yet occurred by the date established 
to initiate data analysis.  Of importance to note, several of the health care providers documented 
that referrals were provided for an additional 17 participants, but in actuality these were not 
ordered.  Had this been accurately performed, the HRBC referrals would have increased by 
29.8% to a total of 74.  Suspected reasons these referrals may not have ordered include a 
miscommunication between the health care provider and the MA or if the participant changed 
her decision after the appointment with the provider had concluded.  Lower than anticipated 
rates of referral acceptance and completion occurred, which impacted the number of women 
overall who could participate in appropriate medical management for their increased risk for 
breast cancer.  Potential participant-related concerns regarding performing HRBC consultations 
are considered further in this chapter.    
 Factorial ANOVA test results for providing a HRBC referral were statistically significant 
for: (1) The health care providers (F(6, 1860) = 9.24, p < .001), (2) the pre- and post-
implementation groups (F(1, 1860), = 22.01, p < .001), and (3) the interaction between the 
health care providers and the pre- and post-implementation groups (F(6, 1860), = 9.23, p < 
.001).  Statistical significance for analysis was established at p < .05.  With the Chi-square 
analyses indicating the two groups were dependent of each other, the ANOVA results 
determined that the protocol implementation utilizing the B-RST™ assessment to guide ordering 
HRBC referrals resulted in an increase in this performance.  With Tukey HSD post hoc test 
results, eight pairs of the health care providers were statistically different from one another in 
regard to ordering HRBC referrals.  Since the EBP protocol adherence and HRBC referral 
provision varied per provider, this consequently affected whether an eligible participant would 
receive a referral and is an additional area needing improvement.   
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Genetics Referral Candidates and Referrals Provided 
 A total of 174 (17.5%) participants had positive-high risk B-RST™ results and were 
appropriate for genetic consultation referrals, in which 32 (18.4%) were ordered, and seven 
(21.9%) were completed.  This is a four-fold rise in referrals for genetic counseling in contrast to 
the eight provided to the pre-implementation group.   
 Three appointments were scheduled and then either not attended or cancelled, and 
have since not been re-scheduled.  An additional 15 participants were candidates for genetics 
referrals, but these were not ordered despite being documented by the health care providers as 
having occurred.  If these had been completed, the total referrals would have increased by 
46.9% to 47.  Similarly to accepting and performing HRBC referrals, those for genetics were 
also less than expected.  Participant-related barriers for utilizing genetic services are explored 
further in this chapter.      
 Comparable to the HRBC referral outcomes, the factorial ANOVA results for providing 
genetic referrals were also statistically significant for: (1) The health care providers (F(6, 1860) = 
5.36, p < .001), (2) the pre- and post-implementation group (F(1, 1860) = 10.14, p < .001), and 
(3) the interaction effect between the health care providers and the groups (F(6, 1860) = 6.46, p 
< .001).  Utilization of the B-RST™, as demonstrated by the significant differences between the 
pre- and post-implementation groups, supported the increase in genetics referrals.  Tukey HSD 
post hoc results revealed statistical difference between three pairs of the health care providers 
for ordering genetics referrals.  Likewise, further focus on the health care providers ordering 
genetics referrals could potentially enhance appropriate participants being provided referrals.  
Primary and Secondary Outcomes 
 Primary outcomes.  The primary outcomes for this EBP project were the identification 
and referral of women considered to be at increased risk for hereditary breast cancer through a 
B-RST™ assessment.  Chi-square test results for the pre- and post-implementation groups 
indicated that the demographic variables of age, appointment type, insurance coverage, race, 
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and religious preference were independent of each other, with p > .05.  Factorial ANOVA results 
were statistically significant (p < .01) for the changes in the HRBC and genetic referrals ordered 
by the providers for the pre- and post-implementation groups.  As evidenced by the data 
analysis and supported in the literature, following the protocol and using the B-RST™ was an 
effective process for recognizing and providing referrals for women at-risk for hereditary breast 
cancer.  In comparison to the HRBC referrals ordered for the pre-implementation group (n = 6), 
51 additional referrals were provided to the post-implementation group (n = 57).  Similarly, 
genetics referrals increased by 24 from the pre-implementation group (n = 8) to the post-
implementation group (n = 32).  Patients at this Ob/Gyn practice will benefit from continued use 
of this risk assessment tool to guide the referral process.    
 According to the EBP project’s findings, from the 259 patients that met the protocol 
criteria but did not have the B-RST™ completed it is estimated that approximately 65 (25%) 
would have also been appropriate for receiving HRBC and/or genetics referrals.  Although the 
MAs were responsible for performing and documenting the B-RST™ results in the EMR, the 
health care providers also had access to this risk assessment tool and were ultimately 
accountable for its performance in patients who met the protocol qualifications.  Increasing B-
RST™ utilization and referral provision are necessary areas of improvement in order to provide 
optimal health care to this high-risk group.     
 Secondary outcomes.  Whereas the primary focus of this EBP project was to both 
identify and provide referrals for women at-risk for hereditary breast cancer, it is essential that 
successful performance of the HRBC and/or genetic consultations occurs for directing medical 
management.  HRBC and genetic consultation participation were secondary outcomes with low 
appointment adherence rates noted for both of these.  By March 1, 2020, a total of eight 
(14.0%) HRBC consultations were performed from the 57 that were ordered and for the 32 
participants who were provided genetic referrals, seven (21.9%) had been completed.  It will be 
advantageous for the patients at this Ob/Gyn practice to receive information about these 
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consultation appointments and to also have their perceived barriers addressed.  Further 
information regarding patient-perceived barriers and recommendations for alleviating these will 
be clarified in the Implications for the Future section of this chapter.  
Comparison of EBP Project Findings to Appraised Literature 
 In accordance with the appraised literature, utilizing the B-RST™ for this EBP project 
was found to be a time efficient approach for accurately identifying and providing referrals to 
women determined to be at-risk for hereditary breast cancer (Anderson et al., 2015; Hilgart et 
al., 2012; Solomon et al., 2016).  The MAs and health care providers reported ease of use with 
performing the B-RST™ assessment, entering results, locating the results in the flowsheet, and 
reviewing these results with the participants.  The uncomplicated nature of using the B-RST™ 
promoted continued use of this risk assessment tool. 
 Although not directly reported by the MAs or the other health care providers, yet noted 
with several of this DNP student’s participants and likewise reported by Baer et al. (2013) and 
Brannon Trexler et al. (2014), when patients inaccurately reported their cancer family history or 
did not perceive sharing this information to be important and simply reported no history, the 
accuracy of the B-RST™ risk appraisal results and consequently the management of these 
results were hindered.  Since one is not able to view both the participant’s cancer family history 
simultaneously while performing the B-RST™ in this health care system’s EMR, the accuracy of 
the cancer family history could not be verified during this process.  However, this information 
could be clarified afterwards with the B-RST™ repeated as needed to ensure accurate results 
and appropriate medical management recommendations. 
 Although each of the health care providers in this Ob/Gyn practice agreed to participate 
in the EBP project and follow the protocol implementation, the adherence rates were quite 
varied.  Two of the three physicians and two of the three midwives consistently did not 
document whether they discussed the B-RST™ results with their patients.  These same 
providers also provided little to no referrals for HRBC and/or genetic counseling.  According to 
HEREDITARY BREAST CANCER PROTOCOL 65 
 
 
Christianson et al. (2012), some of the barriers for optimal risk assessment tool performance 
that presumably applied to the health care providers at the EBP project site included time 
restraints along with knowledge and confidence limitations.  Even though it was not particularly 
time consuming to review results and recommended referrals with the participants, it may not 
have been integrated into the appointment routine for specific providers.  This lack of 
consistency may have consequently affected confidence levels.  In an attempt to improve 
protocol adherence and confidence levels, the providers were contacted several times, in 
person and/or by email or text message, prior to and during the 12-week EBP project to provide 
education regarding: Details of the protocol, the use of the B-RST™, recommended 
management of the three results, and updates regarding data totals (i.e. eligible participants, 
weekly participants, test results, HRBC & genetic referrals).  In addition, the providers were 
requested to provide feedback, which was repeatedly positive.  Despite these favorable 
comments, obstacles persisted for certain providers with ordering referrals.   
 Depending on the location of an office setting, limited resource availability could be a 
barrier to referral and/or genetic testing performance (Berliner et al., 2013; Christianson et al., 
2012).  However, the participants in the EBP study had access to a HRBC with locations within 
the two counties that the Ob/Gyn offices were located.  Although the geneticist worked in only 
one of the two counties, she had two offices for the participants to choose from.  The HRBC had 
limited appointment availability with a maximum of three consultation appointments per week.  
Both of these factors potentially affected the number of consultations completed during this EBP 
project. 
 As evidenced by the literature and supported by the increase in the post-implementation 
referrals for both the HRBC and genetics, incorporating use of a risk assessment tool, such as 
the B-RST™, resulted in a more thorough review, discussion, and management of a patient’s 
family cancer history (Anderson et al., 2015; Baer et al., 2013; Berliner et al., 2013; Kaplan et 
al., 2014).  Although participant feedback was not requested at the time the B-RST™ tool was 
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used, beneficial outcomes were reported to the health care provider during HRBC consultations.  
Consistent with the literature, these benefits included satisfaction with the counseling 
experience related to an increase in knowledge and reassurance about available medical 
management options to decrease specific risk factors (Hilgart et al., 2012; Nelson et al., 2014; 
Obeid, 2017).     
Strengths and Limitations of the DNP Project 
Strengths  
 Staff involved with the project.  Several attributes of this EBP project promoted its 
successful outcomes.  Each of the individuals, involved in varying roles, had essential 
responsibilities for building the foundation of the project.  From the beginning, the health care 
system’s Epic IT representative and the office manager volunteered their time, sharing 
knowledge and skills for the follow EMR tasks: Adding the B-RST™ hyperlink, creating and 
running reports, and performing chart audits.  Aspects of these processes were tedious at times, 
yet the final outcomes allowed the paper version of the B-RST™ to be averted and also reduced 
the time required for data collection.  In addition, each of the nine providers at the project site 
were supportive and willing to participate.  Their buy-in fostered a more positive response from 
the MAs to participate in their roles for this project.  The MAs not only appeared supportive of 
the EBP project, but were competitive amongst each other, as they attempted to achieve the 
highest B-RST™ accuracy rates and have their names chosen for one of the gift cards drawn 
every two to three weeks.   
 Participants.  Both the pre- and post-implementation groups were adequate in size, with 
880 and 994 respectively, and Chi-square analyses indicated the demographics of both these 
groups were a representative sampling of the patients seen at this Ob/Gyn office site.  The DNP 
student did not receive any information regarding negative feedback from the participants who 
had the B-RST™ performed.  For the majority (75%) of the participants, the results were 
negative-average risk with the convenience of no further follow-up being necessary.   
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 B-RST™ utilization and data collection.  As documented in the literature, the B-RST™ 
was simple for the MAs to use and the health care providers to interpret results.  The simplicity 
of performing this assessment promoted protocol adherence, with the goal of ≥ 75% compliance 
achieved.  The hyperlink to the B-RST™ remains in the EMR with the continued accessibility 
allowing sustainability of utilizing the risk assessment tool and following the EBP protocol well 
beyond the 12-week EBP project.  Creating and running reports in the EMR saved time from 
having to search for each participant’s demographic variables. 
 EBP model.  The seven steps of the Iowa Model were valuable in guiding the process of 
performing this EBP project from onset to completion.  This EBP model was chosen related to it 
repetitively being the foundation for successfully implementing changes, such as guidelines or 
protocols, in a variety of health care settings (Iowa Model Collaborative et al., 2017).  Choosing 
the EBP topic and identifying the project focus accomplished the initial two steps.  A unique 
aspect of the Iowa Model were the three check points placed at stages in the process where it 
was necessary to determine if it was appropriate to proceed to the next step, or if further 
progress was needed to accomplish that current step.  As the PICOT for this EBP project was 
finalized, the first checkpoint was achieved.   
 The third step involved choosing team members, which included the: Epic IT 
representative, office manager, nine health care providers, and the MAs.  Key stakeholders 
included one primary MA for each health care provider, with these individual recruited by the 
DNP student based on knowledge of their clinical strengths and interest in the project’s focus.  
The three NPs spontaneously assumed these roles and proved helpful in providing guidance to 
the physicians and MAs regarding B-RST™ use and referral provision.  Upon completing the 
collection and review of the appraised evidence, the fourth step was completed.  At this second 
checkpoint, it was determined the evidence attained not only supported the change but was also 
relevant to this Ob/Gyn practice.   
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 During the fifth step, the pilot process was determined to be successful after collecting 
and evaluating the data for the first two weeks of the protocol implementation.  Feedback from 
the MAs and health care providers was requested, which was positive in nature.  Tips were 
provided for increasing accuracy of the B-RST™ utilization and ordering referrals as applicable, 
along with encouragement for the successful launch of this project.  This was one of the most 
critical and gratifying steps to accomplish and upon doing so, the final checkpoint was achieved.    
 Establishing the EBP change as a permanent practice along with disseminating the 
project findings were the final two steps.  The objective from the beginning of this EBP project 
was to develop a protocol that could prevail beyond the 12-week implementation.  This has 
been the most difficult step and task to achieve.  One of the NPs has continued to have her MA 
complete the B-RST™ once yearly on all patients who are 18 years of age or older.  Although 
12 weeks seemed adequate for developing a permanent change, several of the providers are 
utilizing the B-RST™ on an as-needed basis; this is primarily if they are uncertain if a patient is 
at-risk and eligible for referrals to the HRBC and/or for genetic counseling.  One of the CNMs 
shared that she had not remembered to use the B-RST™ since her MA had stopped routinely 
performing the assessment for her patients; she added that she did know she continued to have 
access to the B-RST™.  It was recognized that one of the physician’s interest with using the B-
RST™ diminished during his last few months before retiring.  Results from the EBP project were 
shared with the health care providers and MAs after data analysis.  Upon completion, the poster 
along with pertinent portions of the presentation material will be shared with the staff at the 
Ob/Gyn practice.  This DNP student will continue to communicate with these providers about 
the benefits of using the B-RST™, in addition to addressing concerns, with the goal of 
consistent B-RST™ utilization and subsequent ordering of HRBC and genetic referrals.     
 The Iowa Model was a good fit for both the topic and office setting where it transpired.  
Minor changes occurred throughout the process that did not require repeating any steps or 
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varying from the intended course of action. The Iowa Model promoted a successful EBP project 
experience for all involved in this protocol implementation.     
Limitations  
 Staff involved with the project.  While challenges with performing the EBP project 
were certainly expected, some barriers and confounding factors encountered were not 
anticipated.  Although each of the health care providers agreed to participate, the level of 
cooperation varied.  It is surmised that some of the providers may have been agreeable to 
participate due to wanting to satisfy the request, or not wanting to disappoint, one of their 
colleagues.  Over time, this could have consequently led to an increased probability for 
diminished interest and involvement in the EBP project and protocol participation.  Despite 
multiple attempts being made, the efforts of the DNP student providing different forms of 
communication with the objective to motivate and support continued and/or improved 
adherence, may not have been adequate when faced with the busy professional schedules 
confronted by the individual providers.  Likewise, it was a challenging role to balance not being 
overly assertive yet still adequately disseminating the areas of improvements necessary for 
correctly following the protocol.  
 Several staff changes occurred with the MAs at this Ob/Gyn practice during the 12 
weeks that the EBP project took place.  During the immediate time frame leading up to and 
during the EBP project there were new MAs hired and resource staffing was utilized.  Although 
the new and resource MAs were educated about the protocol and their roles in the EBP project, 
the levels of commitment seemed less than that of the established staff.  Accordingly, if the MA 
did not perform the B-RST™, it was uncommon that the provider would do so him or herself; 
this in turn affected the amount of patients (n = 259) who were eligible but did not have the B-
RST™ assessment performed.  Despite multiple reminders, the patients whom the MAs 
repetitively missed performing the B-RST™ assessment the most were new patients, and 
particularly those presenting to initiate OB care.  In hindsight, it may have been best to have the 
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EBP project focus on only one group of patients, such as routine gynecological examinations, to 
allow less confusion regarding who was and was not eligible.  In addition, participation was 
reduced from approximately the eight-week time period to the conclusion of the project.  Factors 
may have included the holidays celebrated (Thanksgiving and “Black Friday”) and upcoming 
(Christmas), MAs and health care providers taking vacation days prior to the end of the year, or 
diminishing interest as the project continued.   
 Participants. The participants from this Ob/Gyn setting were an average age of 45 
years old, Caucasian or white, Christian, and had commercial insurance.  These demographics 
may limit the generalizability of the findings to other populations of interest.  Total rates for 
HRBC and genetics referrals provided and performed were low as many participants either 
declined or accepted and then did not schedule a consultation.       
 B-RST™ utilization and data collection.  Despite the straightforward use of performing 
and entering the B-RST™ results in the EMR, the MAs would intermittently skip this task, which 
affected the protocol adherence rate.  Reminders were provided in person or by email if trends 
were noted.  A time-consuming aspect for data collection was developing the template for 
running the weekly chart reports.  After multiple attempts to include the appointment type in the 
data by the Epic IT representative, this DNP student, and the office manager, it was ascertained 
that this information would have to be verified through a chart audit of the daily schedule.  In 
addition, for the two NPs who saw patients from their collaborative physician’s schedule, it was 
difficult at times to accurately ascertain which provider to assign the participant to.  In many 
cases, both the NP and the physician documented in the participant appointment notes.  
Therefore, in an effort to not alter the accuracy of the data, the participants seen collectively by 
the NPs and physicians were grouped together for data collection and analysis.      
Implications for the Future 
 Several recommended areas for health care priorities and/or future research were 
proposed in the appraised evidence.  A common objective was establishing the most 
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advantageous methods for identifying candidates appropriate for medical management along 
with effective approaches for delivering genetic services (Hilgart et al., 2012; Nelson et al., 
2014; Obeid, 2017).  Nelson et al. (2014) also encouraged educating at-risk individuals about 
resources available to assist with improvements in overall knowledge and testing performance. 
 Some of the authors suggested performing a revision of their studies in order to expand 
upon their previous results.  This included incorporating a hereditary breast cancer risk 
evaluation tool into the EMR for more convenient and comprehensive use, such as the method 
used for this EBP project (Kaplan et al., 2014).  To assist with substantiating their prior cross-
sectional study results, Solomon et al. (2016) proposed replicating their study in which the Claus 
model would be used in a larger and more diversified sample population.  Hilgart et al. (2012) 
and Baer et al. (2013) emphasized additional studies should concentrate on the psychological 
effects and long-term consequences of testing positive for a cancer gene mutation. 
  Brannon Trexler et al. (2014) proposed investigating methods for collaborating with an 
individual’s family members who were affected by cancer and therefore more appropriate for 
genetic consultations and testing.  Anderson et al. (2015) considered the following health care 
provider-focused study topics for the most advantageous methods to analyze: (1) Determining 
best practice knowledge related to breast cancer risk appraisal; (2) improving confidence with 
having conversations with patients about their risk for breast cancer; and (3) enhancing overall 
quality of exchanging information with patients.   
Conducting EBP projects or studies concentrated on any of the aforementioned 
recommendations could strengthen the ability for health care providers to determine the optimal 
methods for identifying women at-risk for hereditary breast.  Consequently, these methods 
should also include improving the utilization of genetics services.  In regards to the health care 
providers and participants who participated in the EBP project, the most applicable future 
recommendations include: (1) Maintaining current knowledge about hereditary breast cancer, 
associated risks, and use of screening tools (such as the B-RST™) to accurately and promptly 
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identify these individuals, (2) enhancing confidence with reviewing risk assessment results and 
risk factors, and (3) improving discussions with at-risk patients about management options, such 
as referrals to the HRBC and/or genetics, including expectations from these consultations.  At 
the EBP project site, one or more of the health care providers could present up-to-date 
information on these topics to their colleagues.  Dialogues could be shared with tips for 
discussing risk assessment results, medical resources, patient perceived barriers, and common 
questions.  As more patients are determined to be at-risk and subsequent conversations occur, 
it is expected the providers will gain confidence in methods to best deliver this information to 
their patient population.     
 Addressing barriers to completing genetic counseling.  Low participation rates for 
genetic counseling were noted with this EBP project and commonly reported in the literature.  In 
a study performed by Wernke et al. (2019), from the 35 women who had negative-moderate or 
positive B-RST™ results, 24 were interested in attending a complimentary genetics 
appointment, 20 scheduled an appointment, and only four completed genetic counseling.  The 
genetics consultation participation rate from the EBP project (21.9%) was comparable to the 
results from this study (20%) (Wernke et al., 2019).  Correspondingly, a 16% genetics referral 
completion rate was noted with a study performed by Hoskins et al. (2018).  These authors 
reported that the leading challenges expressed by their participants regarding completing a 
genetic consultation included not perceiving the appointment as being a priority and the time 
commitment.  For the study by Wernke et al. (2019), offering genetic counseling free of charge 
removed the potential barrier of concern regarding cost.  However, studies have shown that 
financial concerns have been linked with underutilization of genetic services (Hayden, Mange, 
Duquette, Petrucelli, & Raymond, 2017; Kne et al., 2017).  Additional patient reported barriers 
hindering genetic consultation completion consisted of: (a) lack of perceived benefits, (b) 
inaccurate cancer risk perception, (c) insufficient knowledge and/or confidence about the 
process of genetic counseling, (d) apprehension regarding privacy, (e) fear of positive genetic 
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results and potential impact thereof, (f) concerns regarding the opinions and potential lack of 
support family members, (g) disinterest in changing medical management despite test results, 
and (h) referral location too far away (Houfek, Soltis-Vaughan, Atwood, Reiser, & Schaefer, 
2015; Kne et al., 2017; Wernke et al., 2019).  Health care providers should inquire about 
reasons that a patient may be hesitant and/or declines a referral; accordingly, this knowledge 
can promote a discussion addressing reported barriers and providing information to help the 
individual with this important decision-making process (Kne et al., 2017). 
 Since a patient’s decision whether to pursue genetic services can be multi-faceted, in 
addition to addressing barriers, the health care provider should also focus on the benefits of 
genetic counseling.  McAllister and Dearing (2015) performed a literature review and concluded 
that patient empowerment was the primary benefit reported by individuals who completed 
genetic counseling.  Further benefits comprised: (a) the ability to reduce or eliminate specific 
cancer risks, (b) a gain in knowledge regarding specific cancer genetic disorders, (c) the 
potential positive effects the knowledge about test results has on family members, and (d) the 
ability to establish long-term medical plans (Houfek et al., 2015).  Although it is more practical 
for the patient to make a decision during their appointment, providing a handout that focuses on 
the benefits of genetic counseling and addresses common barriers may not only enhance the 
patient’s knowledge and assist with decision-making, but also allow this process to be more 
efficient for the health care provider. 
Practice 
 The findings of this EBP project supported the routine use of the B-RST™ assessment 
as a best practice recommendation.  At the EBP project site, it was demonstrated that utilizing 
the B-RST™ was a simple process for the MA, health care provider, and the patient.  With the 
majority (75%) of the results being negative-average risk, it was less common that additional 
time was needed to review these results and further recommendations.  However, it remains a 
valuable use of time educating patients about pertinent risks along with options to pursue for 
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decreasing these accordingly.  With the B-RST™ remaining in the EMR flowsheet section of a 
patient’s chart, this risk assessment tool remains available to the health care providers at this 
Ob/Gyn practice.  In addition, it is available to the other health care providers who work in office 
settings for this health care system.        
Theory 
 In order to best guide medical management of women at-risk for hereditary breast 
cancer, it is important for health care providers to be knowledgeable about patient-perceived 
barriers to participating in HRBC and/or genetic counseling.  Correspondingly, the Health Belief 
Model is based on the awareness of an individual’s perceptions towards preventive health care 
activities, with communication being an important component (Jones et al., 2015).  If an 
individual does not identify as being at-risk for hereditary breast cancer, the likelihood that 
referral acceptance will occur diminishes.  In addition, referral participation is unlikely despite an 
individual being aware of this risk, if personal advantages are not recognized to furthering 
knowledge about approaches to eliminate or reduce risk factors.  Thoroughly discussing the 
process of a referral, barriers, and benefits, coupled with answering questions, can assist 
individuals with more accurately understanding their risks and the positive contributions of 
performing HRBC and/or genetic counseling.   
Research 
 The findings of this EBP project were consistent with the literature indicating an 
underutilization of genetic services.  Future EBP projects and research should focus on 
addressing and overcoming patient-reported barriers with the goal of increasing patient 
participation rates.  Timely follow-up is necessary for educating women at-risk for hereditary 
breast cancer about medical management options that promote breast cancer prevention or 
early detection (Kiely & Schwartz, 2014).  It would be beneficial to determine optimal methods 
for providing and reviewing information about what occurs at consultation appointments to 
stimulate further discussion and promote consultation participation.  This can also vary 
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depending on the demographics of a patient population.  Determining the best approach at this 
EBP project site may necessitate the health care providers specifically inquiring if patients with 
negative-moderate or positive-high risk results have questions, concerns, or reservations about 
having HRBC and/or genetic counseling performed.  The health care providers could then share 
this information with their colleagues in an attempt to more adequately meet this health care 
need for their patient population.     
Education 
 Breast cancer is the leading new cancer diagnosis and the second highest cause of 
cancer death in American women (ACS, 2019).  Approximately 90% of individuals who have a 
breast cancer gene mutation that can cause hereditary breast cancer are not knowledgeable 
about this diagnosis (Drohan et al., 2012).  Consequently, it is imperative that not only health 
care providers, but MAs, nurses, and students (MAs, nursing, APRNs, Physician Assistants, 
and medical), are educated and remain up to date about this significant risk factor.  Health care 
providers can read and discuss current studies with their colleagues.  In-services and genetic 
testing company sponsored activities can occur to educate multiple staff members as a group.  
Case studies from patients within a practice can be discussed.  Key stakeholders, such as those 
depicted in the Iowa Model, can assist with arranging the preceding activities.  Regardless of 
the scheduled reason for a patient’s appointment, in the pursuit of preventive health care, the 
health care provider should take the opportunity to perform a risk assessment, discuss the 
results, provide additional education as needed, and order appropriate referrals.   
Conclusion 
 Findings from this EBP project supported the use of the B-RST™ as an effective method 
for identifying women who are at-risk for hereditary breast cancer at an Ob/Gyn office setting.  
Improved MA and health care provider adherence to performing and utilizing the B-RST 
assessment is necessary; this coupled with an increase in HRBC and genetics referral provision 
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and performance, can effectively aid in the diagnosis and management of hereditary breast 
cancer gene mutations with the overall goal of promoting optimal health outcomes.  
Recommendations for the EBP project site include: (1) Continue B-RST™ assessment once 
yearly for all patients and repeat if personal or family cancer history changes, (2) increase 
documentation if HRBC or genetics referrals are offered, accepted, and/or declined, and (3) 
provide patient-reported reason(s) for a referral being declined to aid in improving genetic 
counseling participation rates.  Considerations for the general field of health care are to: (1) 
Promote health care provider awareness about genetic risk assessment tool use (such as the B-
RST™) and (2) enhance recognition of barriers to providing, accepting, and performing referrals 
to properly address these concerns with the goal of increased referral participation.  The more 
the B-RST™ assessment is performed, the more lives that can be positively affected.        
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Appendix C 
Evidence Data Table 
 
Citation 
 
 
Population, Setting(s) 
 
Intervention(s), 
Comparison(s) 
 
Outcomes, Effect 
Measures 
 
 
Level of 
Evidence, 
Grade 
Anderson et al. 
(2015) 
 
Journal of 
Oncology 
Practice 
 
Breast cancer 
risk assessment 
among low-
income women 
of color in 
primary care: A 
pilot study 
 
 Low income African 
American and 
Hispanic women ages 
25 to 69 years old, 
without a personal 
history of breast 
cancer, presenting for 
annual examinations 
at two federally 
assisted medical 
institutions in the 
Midwest 
 Exploratory Pilot Study 
 
 Study population: N = 237 
 
 Prior to examination with 
health care provider, the 
following was collected:  
(a) risk factor information, 
(b) baseline survey, and 
for those consenting,  
(c) breast cancer risk 
evaluation using the BC 
Risk Screening (BRS) 
web-based tool, which 
simultaneously calculates 
the following models: (1) 
Claus, (2) modified Gail, 
and (3) pedigree 
assessment tool 
 Outcome:  
   Determining what factors affect 
women’s decisions to either accept or 
decline breast cancer risk evaluation 
performance 
 
 The majority of this population  
(n = 207, 87.3%) chose to be 
informed of their breast cancer risk 
assessment results with an increased 
likelihood with women ages 40 to 49 
years old with OR 5.4 (95% CI, 1.09 - 
26.67) and 50 to 69 years old with OR 
7.99 (95% CI, 1.47 - 43.44) 
 
 Women choosing not to participate in 
risk assessment result discussions (n 
= 30, 12.7%) shared the following 
characteristics:  
(1) younger age (< 40 years old), 
(2) lack of concern regarding personal 
risk for breast cancer, 
(3) prior history of mammogram, and  
(4) lacking private insurance coverage 
 High rate of BRS tool use in this 
population accomplished the 
following: (a) compliance with 2013 
USPSTF breast cancer risk appraisal 
Level III, B 
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recommendations, and (b) in office 
utilization of a tool that efficiently 
performs the appraisal with 
consideration of health care provider 
barriers of time restraints and/or lack 
of breast cancer risk knowledge    
Baer et al. 
(2013) 
 
Journal of 
General Internal 
Medicine 
 
Use of a web-
based risk 
appraisal tool for 
assessing family 
history and 
lifestyle factors 
in primary care 
 
 
 New or established 
female and male 
patients between 18 
to 75 years old, 
without a family 
history of cancer 
documented in their 
EMR, presenting for 
annual examinations 
within five urban 
academic primary 
care medical practices   
 Controlled Trial without 
Randomization 
 
 Study population: 
intervention group from 
three practices (n = 996), 
control group from two 
practices (n = 637) 
 
 Intervention group: Use of 
the Your Health Snapshot 
(YHS) web-based risk 
assessment tool linked to 
the EMR prior to 
appointment with health 
care provider; family health 
history used to evaluate 
risks for cancer (breast, 
colon, lung, and prostate), 
with cancer screening test 
alerts created in the EMR 
for the health care provider  
 
 Follow-up phone call to 
both groups 
 
 EMR review one month 
after visit 
 Primary outcome:  
   New documentation of cancer family 
history in the EMR within 1 month of 
visit 
 
 Secondary outcome:  
   New cancer screening test notices for 
those with an increased risk for breast 
or colon cancer provided by health 
care providers within 1 month of visit  
 
 Individuals in the intervention group 
were more likely to have cancer family 
history addressed with EMR 
documentation than in the control 
group (10.6% vs. 0.8%) with adjusted 
OR 15.9 (95% CI; [3.5, 72.1], p = 
0.003) 
 
 No significant differences between the 
groups for receiving cancer screening 
test notices, with 8 provided to the 
intervention group and 0 to the control 
group, low results were believed due 
to an EMR accessibility issue  
 
 Use of this concise web-based risk 
assessment tool raised the rate of 
cancer family history charting in EMR 
 
Level II, B 
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Berliner et al. 
(2013) 
 
Journal of 
Genetic 
Counseling 
 
NSGC practice 
guideline: Risk 
assessment and 
genetic 
counseling for 
hereditary breast 
and ovarian 
cancer 
 
 Provided by the 
National Society of 
Genetic Counselors 
(NSGC) 
 
 Revised evidence-
based practice 
guideline from 2007 
recommendations for 
health care providers 
caring for women who 
either have or are at 
increased risk for 
breast and/or ovarian 
cancers 
 Clinical Practice 
Guidelines 
 
 Recommendations 
focused on three 
categories:  
   (1) Process for collecting 
and evaluating personal 
and family histories, in 
order to assess women’s 
cancer risks, and provide 
appropriate referrals for 
genetic services 
 
   (2) Cancer risk appraisal 
model use including:  
   (a) BOADICEA,  
   (b) BRCAPRO, (c) Claus, 
(d) Gail, and (e) Tyrer-
Cuzick/IBIS 
 
   (3) Opportunities for 
medical management 
comprising: (a) screening 
tests and examination 
maintenance,  
   (b) medications, and  
   (c) surgical options 
 Best practice recommendations:  
   (1) Consult guidelines to determine if 
a woman is a candidate for cancer 
genetic testing and provide 
individualized health care risk-
reducing strategies 
 
   (2) Consider BRCA and other 
applicable gene mutations  
 
   (3) Perform a cancer risk evaluation 
utilizing models to determine 
subsequent approach for health care 
management 
 
   (4) Determine medical management 
options based on medical expertise, 
cancer family history, assessed risk, 
and outcome of genetic testing 
 
   (5) Arrange referral to a genetics 
professional to provide resources to 
support educational and emotional 
needs 
 
   (6) Explain current, multi-faceted 
consequences of genetic testing 
Level IV, B 
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Brannon Trexler 
et al. 
(2014) 
 
Annals of 
Surgical 
Oncology 
 
Implementing a 
screening tool 
for identifying 
patients at risk 
for hereditary 
breast and 
ovarian cancer: 
A statewide 
initiative 
 
 Primarily minority 
(73.2% African 
American and 8.0% 
Hispanic) and low-
income women ages 
14 to 85 years old 
without a personal 
history of cancer 
obtaining health care 
at one of six 
participating public 
health departments in 
a southern U.S. state 
 Demonstration Project 
 
 Study population:  
N = 2159 
 
 Use of the breast cancer 
genetics referral screening 
tool (B-RST™), while 
attaining the medical 
history prior to health care 
provider examination, to 
identify and manage 
appropriate at-risk women 
 
 Staff educated on 
hereditary breast and 
ovarian cancer (HBOC) 
syndrome and how to use 
the B-RST™ through the 
following: (a) personal 
stories of women with a 
BRCA gene mutation,  
(b) surgeon presentations,  
(c)  observation and use of 
the B-RST™  
 
 
 Outcomes:  
   (1) Integrating the B-RST™ within this 
selected minority population to 
recognize women with increased 
HBOC risk 
 
   (2) Assisting with the health care 
management of those having positive 
B-RST™ results 
 
   (3) Educating staff about cancer 
genetic topics with the goal of 
accurate utilization of the B-RST™ 
 
 Of the participants:  
   (a) 130 (6.0%) had positive B-RST™ 
results, and 
   (b) 110 (84.6%) then consented to be 
contacted, with 
   (c) 67 (60.9%) then provided 
clarification of family history 
   (d) 47 (42.7%) of these women were 
successfully contacted and 
determined to be appropriate for 
testing per current medical society 
guidelines, and 
   (e) 14 (12.7%) performed cancer 
genetic testing, with 
   (f) 1 (7.1%) woman being diagnosed 
with a BRCA2 gene mutation 
 
 Use of the B-RST™ promoted 
identification of woman at-risk for 
hereditary HBOC; knowledge 
increased in staff as demonstrated by 
improved post-activity test results 
Level III, A 
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Christianson et 
al.  
(2012) 
 
Journal of 
Genetic 
Counseling 
 
The use of a 
family history 
risk assessment 
tool within a 
community 
healthcare 
system: Views of 
primary care 
providers 
 Health care providers 
with a variety of 
specialties and an 
average of 23 years of 
experience from a 
community-based 
medical system on the 
East Coast 
 Qualitative Study 
 
 Study population: N = 16, 
with 14 physicians and 2 
mid-level providers from 9 
medical practices 
 
 Three focus meetings with 
discussion of nine 
questions related to 
current practice and future 
use of the MeTree risk 
assessment tool at a local 
oncology center, with 
subsequent shared 
obligation of these results 
with a patient’s primary 
care health care provider  
 
 MeTree is a web-based 
tool for evaluation of 
inherited risks for breast 
and colon cancers, in 
addition to thrombophilia 
disorders 
 Outcome:  
   Determine health care provider 
perceived challenges with integration 
of a risk appraisal tool to resolve 
these factors and improve its future 
utilization 
  
 Data coded and analyzed with themes 
categorized into the following:  
   (1) current methods for evaluating risk 
of medical conditions  
 
   (2) barriers associated with obtaining 
and using family health histories  
 
   (3) challenges associated with 
applying family history to 
individualized health care strategies  
 
   (4) obstacles with performance of the 
MeTree tool at the oncology center  
 
   (5) medical and educational needs 
 
 Consideration and alleviation of 
anticipated health care provider and 
patient challenges, with the availability 
of necessary resources, are essential 
components to consider prior to  
implementation of a risk assessment 
tool 
Level III, 
A/B 
Hilgart et al. 
(2012) 
 
Cochrane 
Database of 
 Females and males 
across the lifespan (a) 
at risk for breast 
cancer due to family 
history, (b) without a 
 Systematic Review  
   (of RCTs) 
 
 Performed to update 2007 
systematic review 
 Outcomes for those at increased risk 
for familial breast cancer with 
assessment of: 
 (1) Methods for performing risk     
evaluation 
Level I, A 
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Systematic 
Reviews 
 
Cancer genetic 
risk assessment 
for individuals at 
risk for familial 
breast cancer 
(Review) 
 
 
personal history of 
breast cancer, and (c) 
with or without a 
known BRCA gene 
mutation 
 
 
 
 Total of 8 RCTs, with 5 (N 
= 1973) new to this update 
    
 Study interventions 
comprised:  
 Individual vs. group 
genetic counseling 
(include # of studies 
focused on each topic) 
(2) 
 Surgical consultation 
with or without hereditary 
risk assessment (1) 
 Web-based risk 
assessment tool used in 
a clinic (1) 
 Community vs. regional 
genetic services (1) 
 Phone vs. in-person 
counseling (1) 
 Counseling performance 
vs. delayed counseling 
(3) 
 Provision of a letter vs. 
in-person consultation 
(1) 
 Appraisal of  
psychological effects of 
cancer risk evaluation (8)   
 
 (2) Approaches for providing genetic    
health care 
 
 (3) Differences between risk 
evaluation performed by a genetic 
specialist or a non-genetic specialist 
 
 Studies revealed genetic services 
provide: (a) a decrease in cancer 
anxiety and enhanced emotional well-
being; (b) increased personal risk 
perception accuracy and knowledge 
concerning breast cancer and genetic 
services, and (c) overall satisfaction 
with use of genetic services 
  
 With the benefits of genetic services 
considered to outweigh the harms, 
recommendation that a hereditary 
breast cancer risk assessment is 
performed to determine if a referral for 
genetic consultation is appropriate  
Kaplan et al. 
(2014) 
 
Cancer 
Epidemiology, 
Biomarkers & 
 Women ages 40 to 74 
years old without a 
previous history of 
breast cancer 
receiving health care 
at two U.S. 
 Randomized Controlled 
Trial  
 
 Study population: 
intervention (n = 580) and 
control (n = 655); 
 Outcomes: 
   (1) Frequency of patient-provider 
breast cancer risk and risk reduction 
conversations 
   (2) Genetic services referrals 
   (3) EMR reporting of these activities   
Level I, B 
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Prevention 
 
A randomized, 
controlled trial to 
increase 
discussion of 
breast cancer in 
primary care 
 
 
metropolitan primary 
care medical offices 
 
 
randomized after baseline 
phone interviews using 
statistician-developed 
sequence codes 
 
 Intervention of breast 
cancer risk assessment 
using an office-based web-
based tool, BreastCARE, 
to stratify breast cancer 
risk using the follow for risk 
appraisals: (a) Referral 
Screening Tool, (b) Gail 
Model, and (c) Breast 
Cancer Surveillance 
Consortium risk model   
 
 Interventions:  
   (a) Baseline phone 
interviews and risk 
assessment, (b) 
BreastCARE tablet use, (c) 
one to two week post-visit 
phone survey, (d) six 
month post-visit EMR 
review 
 
 BreastCARE use increased frequency 
of patient-provider discussions 
regarding:  
   (a) cancer family history, OR 2.07, 
95% CI [1.34, 3.20] 
 
   (b) breast cancer risk, OR 4.78, 95% 
CI [2.90, 7.89] 
 
   (c) genetic services, OR 5.99, 95% CI 
[2.69, 13.3]  
 
   (d) high-risk clinic referral, OR 5.32, 
95% CI [2.21, 12.8] 
 
 BreastCARE use increased 
documentation in intervention vs. 
control groups:  
   (a) cancer family history (10.2% vs. 
5.5%, p = 0.006) 
 
   (b) breast cancer risk (5.3% vs. 0.2%, 
p < 0.001) 
 
   (c) genetic services (3.3% vs. 0.9%, p 
= 0.005) 
 
 Especially for women at risk for 
hereditary breast cancer, use of a 
web-based risk appraisal tool 
increases risk and medical 
management options conversations 
Nelson et al. 
(2014) 
 
 Population of interest: 
Women across the 
lifespan provided 
 Systematic Review  
   (of multiple study types) 
 
 Outcomes of benefits and harms 
assessed in three areas:  
(1) BRCA risk evaluation tool use  
Level III, A 
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Annals of 
Internal 
Medicine 
 
Risk 
assessment, 
genetic 
counseling, and 
genetic testing 
for BRCA-
related cancer in 
women: A 
systematic 
review to update 
the U.S. 
Preventive 
Services Task 
Force 
recommendation 
 
 
health care in 
locations similar to the 
U.S. without a 
personal history of a  
BRCA gene mutation 
or BRCA-related 
cancer(s)  
 
 Models/tools used in 
the following 
countries: Brazil, 
Canada, United 
Kingdom, and the 
U.S. 
 Performed to update 2005 
USPSTF 
recommendations 
 
 Total of 27 studies, with 16 
new for this update 
(including RCTs, 
systematic reviews, cohort, 
and case-control studies) 
 
 Variety of interventions 
measuring: (a) five risk 
models/tools; (b) risk 
perception and cancer 
worry; and (c) tests, meds, 
and surgeries to decrease 
risk of BRCA-related 
cancers 
(2) Genetic services results  
(3) BRCA management options for 
malignancy and mortality reduction 
 
 Comparison of sensitivity between 
risk models/tools, with the Referral 
Screening Tool having a high 
sensitivity (>89%) 
 
 Risk perception accuracy generally 
increased and worry decreased after 
genetic counseling  
 
 Best practice recommendation:  
   Weigh individualized benefits, harms, 
and risks when assessing risk, 
referring for genetic services, or 
offering medical management to 
decrease cancer risk; more studies 
recommended  
 
 Unable to perform quantitative meta-
analysis due to study heterogeneity 
Obeid 
(2017) 
 
The Joanna 
Briggs Institute 
EBP Database 
 
Breast cancer 
(familial): 
Classification 
and care. JBI 
Evidence 
Summary 
 Population of interest: 
Women across the 
lifespan at increased 
risk for hereditary 
breast cancer being 
provided primary, 
secondary, and 
tertiary levels of health 
care  
 Evidence Summary 
 
 Resources included two 
Cochrane Database 
systematic reviews, 
evidence from the National 
Institute for Clinical 
Excellence, and one each 
of the following: meta-
analysis, RCT, cross-
sectional observational 
study, epidemiological 
study, and literature review 
 Best practice recommendations for: 
(1) patient-focused care; (2) cancer 
family history and provider referral;  
(3) screening; and, (4) genetic 
services 
 
(1) Patient-focused care: Respecting 
patient’s personal decisions, providing 
educational handouts, determining 
and discussing risk level, 
communicating effectively, involving 
family members when appropriate 
(grade B) 
Level IV, A 
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(2) Cancer family history and provider 
referral: Evaluating breast cancer risk 
by obtaining a history including first 
and second- degree family members, 
creating protocols incorporating 
referral process (grade B) 
 
(3) Screening: Recommending 
mammography, considering adding 
magnetic resonance imaging (MRI) as 
indicated, considering gene mutations 
specific to cancer family history 
(grade B) 
 
(4) Genetic services: Assessing risk 
and referring appropriate candidates 
for genetic counseling with potential 
testing (grade B) 
Solomon et al. 
(2016) 
 
BMC Family 
Practice 
 
Contribution of 
extended family 
history in 
assessment of 
risk for breast 
and colon 
cancer 
 Women with an 
average age of 63 
years old receiving 
services at a 
mammography center 
in a Northeastern U.S. 
city 
 Cross-Sectional Study 
 
 Study population (N = 499) 
 
 Questionnaire completion 
at time of mammography 
services 
 
 Recommendation of 
additional breast medical 
management options 
based on the use of the: 
(1) ACS and NCCN 
screening guidelines,  
(2) Claus model for breast 
cancer risk estimation, and 
(3) breast cancer genetics 
referral screening tool 
 Outcomes: Identification and 
comparison of individuals qualifying 
for cancer genetic services based on 
either limited/first-degree or 
comprehensive/first and second-
degree family histories in order to 
determine appropriate candidates for 
genetic services referrals 
 
 Applying ACS guidelines, 22% of at-
risk women qualifying for genetic 
services were missed using 
limited/first-degree family history 
 
 Using the Claus model, 3.6% (n = 18) 
had more than a 20% lifetime breast 
cancer risk, with 5 of these 18 women 
recognized using limited/first-degree 
Level III, B 
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(RST)  
 
 
family history 
 
 Using the RST, 1.8% (n = 9) qualified 
for breast cancer genetics referral, 
with 7 of these 9 women recognized 
using limited/first-degree family 
history  
 
 Accurate cancer genetic risks require 
obtaining and evaluating 
comprehensive/first and second-
degree family histories 
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Appendix D 
Permission to Use B-RST™ 
Bellcross, Cecelia A.  
 
Wed, Jul 10, 2019 9:17 AM  
 to me  
 
 
Hi Chrys –  
  
Thank you for your interest in B-RST™.  You can view the most updated version at 
www.brcagenescreen.org.  The attached paper describes the validation. 
  
What needs to be done on your end depends on how you/Epic are going to use it.  If you are just 
going to create a hyperlink using the above URL, no specific licensing is required, and you have 
my permission. 
  
If however, EPIC wants to imbed the program within the EMR, this would require a licensing 
agreement as the program/algorithm is intellectual property owned by Emory.  Doing the latter 
can allow for direct integration of the result report into the EMR, as well as interface 
customization.  The licensing agreement would need to be with EPIC, and they would pay the 
associated fee.  This would also allow them to market it as part of their EMR package to others. 
  
Please let me know which of the above options you are interested in.  I’m happy to discuss by 
phone if it is helpful. 
  
Best, 
  
Cecelia 
  
Cecelia A. Bellcross, PhD, MS, CGC 
Associate Professor 
Director, Genetic Counseling Training Program 
Emory University School of Medicine 
Department of Human Genetics 
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Appendix E 
B-RST™ Results Patient Handout 
Understanding Your Breast Cancer Genetics  
Referral Screening Tool (B-RST™) Results 
 Negative – Average Risk 
 According to the information you provided today, your results indicate that you have an average 
risk for breast and/or ovarian cancer to occur  
 Based on your personal & family cancer history, you are not likely to have inherited a BRCA gene 
mutation that can significantly increase your risk for breast and/or ovarian cancer 
 If you are at the appropriate age, you should have screening mammography according to your 
health care provider’s recommendation based on current guidelines 
 Negative – Moderate Risk 
 According to the information you provided today, your results indicate that you have a moderate, 
or greater than average, risk for breast and/or ovarian cancer to occur  
 Based on your personal & family cancer history, you are not likely to have inherited a BRCA gene 
mutation that can significantly increase your risk for breast and/or ovarian cancer 
 If you are at the appropriate age, you should have screening mammography according to your 
health care provider’s recommendation based on current guidelines 
 You should consider a consultation at the High Risk Breast Clinic through St. Mary Medical 
Center (locations in East Chicago, Hobart, Munster, and Valparaiso) to discuss management 
options for this increased risk for breast cancer 
 Positive - High Risk 
 According to the information you provided today, your results indicate that you have a high, or 
much greater than average, risk for breast and/or ovarian cancer to occur  
 Based on your personal & family cancer history, there is a possibility you have inherited a gene 
BRCA mutation that can significantly increase your risk for breast and/or ovarian cancer 
 If you are at the appropriate age, you should have screening mammography according to your 
health care provider’s recommendation based on current guidelines 
 You should consider a consultation at the High Risk Breast Clinic through St. Mary Medical 
Center (locations in East Chicago, Hobart, Munster, and Valparaiso) to discuss management 
options for this increased risk for breast cancer 
 You should also strongly consider a consultation with a geneticist to discuss your personal and 
family cancer history in more detail, in order to determine if you are a candidate for cancer 
genetic testing 
 
Note: This screening tool is not a diagnostic test.  Negative-average risk results do not indicate you will 
not ever have breast and/or ovarian cancer occur.  Likewise, negative-moderate & positive-high risk 
results do not indicate you will ever have breast and/or ovarian cancer occur.    
Adapted from the Result sections of the Breast Cancer Genetics Referral Screening Tool (B-RST™), 
brcagenescreen.org, Copyright 2015 - 2019 Emory University, created by Cecelia Bellcross, PhD, MS, CGC 
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Appendix F 
Permission to Adapt B-RST™ Results Section for Patient Handout 
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Appendix G 
B-RST™ Project Tip Sheet for Providers 
 
B-RST™ Project Tip Sheet for Providers 
Who qualifies:  Women > 18 y/o presenting for an annual exam or   
    new patient appointments (only performed once) 
Who does not qualify: Women w/dementia or developmental    
         delays/mental retardation 
 
Steps: 
1.  Results can be reviewed in the Flowsheet tab and will be marked on the 
handout entitled “Understanding Your Breast Cancer Genetics Referral 
Screening Tool (B-RST™) Results” 
2.  1 of 3 results will display upon completing use of the tool (negative-
average, negative-moderate, positive-high) 
3.  Negative-average risk results: Order mammogram as appropriate 
4.  Negative-moderate risk results:  Order mammogram as appropriate, 
offer referral to High Risk Breast Clinic 
5.  Positive-high risk results: Order mammogram as appropriate, offer 
referral for both the High Risk Breast Clinic and for genetic counseling  
6.  It is recommended to note in your charting that the B-RST™ results 
were reviewed and if referral(s) were offered & then accepted or declined 
7.  Please inform me of any questions you or the patients have! 
8.  THANK YOU for participating in my project! 
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Appendix H 
B-RST™ Project Tip Sheet for MAs 
B-RST™ Project Tip Sheet for MAs 
Who qualifies:  Women > 18 y/o presenting for an annual exam or   
            new patient appointments (only performed once) 
Who does not qualify: Women w/dementia or developmental    
              delays/mental retardation 
Steps: 
1.  Go to the Flowsheet tab 
2.  Click on B-RST™ 
3.  Click on hyperlink 
4.  Answer questions with patient 
5.  1 of 3 results will display upon completing use of the tool (negative-
average, negative-moderate, positive-high) 
6.  Enter this result in the 2nd line of the B-RST flowsheet by clicking on the 
magnifying glass & also mark this result on the patient handout, 
“Understanding Your Breast Cancer Genetics Referral Screening Tool (B-
RST™) Results”, & place this handout back in the plastic patient folder for 
the provider to review with the patient 
7.  Patient can refer to the exam room copy of the handout that will be on 
the desk top in a plastic protector  
8.  Place referrals for High Risk Breast Clinic and/or genetic consultations 
as ordered by the provider (common diagnoses will be family/personal 
history of breast cancer, increased risk for breast cancer) 
9.  Please inform me of any questions you, the providers, or the patients 
have! 
10.  THANK YOU for participating in my project!  
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Appendix I 
IRB Determination 
 
